








University of Insubria 
Department of Medicine and Surgery 
PhD in Experimental and Translational Medicine  
XXX cycle 






DNA HYPOMETHYLATION AND 





























INTRODUCTION_____________________________________________________________________________4                                 
1. COLORECTAL CANCER (CRC)……………………………………………………..…….…………….…...…..5 
1.1 EPIDEMIOLOGY AND NATURAL HISTORY……………………………………………………....5 
1.2 RISK FACTORS………………………………………………………………………………………..6 
1.3 SCREENING, STAGING AND PROGNOSIS…………………………………………………….…..7 
2. MOLECULAR PATHWAYS IN CRC……..…………….……………............................................……………...9 
2.1 CIN…………………………………………………………………………………………….……....10 
2.1.1 THE ROLE OF DNA HYPOMETHYLATION IN CRC……………………………………….11 
2.1.2 DNA HYPOMETHYLATION AND OXIDATIVE STRESS…………………………………..15 
2.2 MSI…………………………………………….…………………………………………………..…..16 
2.3 CIMP…………………………………………………………………………………………………...17 
3. HEREDTARY COLORECTAL CANCER SYNDROMES…………………………………...…………………18 
3.1 MUTYH-ASSOCIATED POLYPOSIS (MAP)……………………………………...…………..........18 
3.2 FAMILIAL ADENOMATOUS POLYPOSIS (FAP)………..…………………………..……......…..20 
3.3 LYNCH SINDROME (LS)………..……………………….………………………………..………...21 
4. IDENTIFICATION OF LOW-PENETRANCE ALLELES IN CRC.……….…………………………...……….23 
4.1   THE ROLE OF SINGLE NUCLEOTIDE POLYMORFISM rs1800734 OF MLH1 PROMOTER IN 




MATERIALS AND METHODS________________________________________________________________30                                                                                                                             
FIRST PART    
1. PATIENTS AND SAMPLES……………………………………………………………………………………..31 
2. GENE MUTATIONAL ANALYSIS…………………………………………………………………….....….….33  
3. L1 AND L1-MET METHYLATION STUDY IN HEREDITARY AND SPORADIC ADENOMAS BY 
BISULFITE PYROSEQUENCING ANALYSIS…………………………………………………………………36 
4. MET AND L1-MET EXPRESSION STUDY IN CRCs AND PRENEOPLASTIC LESIONS…………….…….39 
4.1   RNA-SEQ ANALYSIS …………………………………...………………..…………………………39  
4.2   CHARACTERIZATION OF L1-MET CHIMERIC ISOFORM……………………...……………….40 
4.3   MET AND L1-MET GENE EXPRESSION ANALYSIS………………………..…..………………..42  
5. STATISTICAL ANALYSIS…………………………………….............................……………………………...44 
 
SECOND PART 
6. GENOTYPING OF MLH1 PROMOTER rs1800734 BY KOMPETITIVE ALLELE-SPECIFIC PCR 
(KASP)………………………………………………..………………...………………..………………………..45 
7. MLH1 METHYLATION STUDY………………………………………………………………………………...48 
7.1 MISEQ BARCODED AMPLICON BISULPHITE SEQUENCING OF MLH1 CpG ISLANDS AND 
SHORES………………………………………………………………………………………………48 
7.2 MLH1 PROMOTER METHYLATION ANALYSIS USING MS-MLPA………………………...…51 
8. MLH1 TRANSCRIPTIONAL ANALYSIS……………………………………………..……………….………..53 









1. GENE MUTATION ANALYSIS…………………………………………………….....………...….………..…57 
1.1 KRAS, NRAS, BRAF AND PI3KCA MUTATION ANALYSIS IN COLORECTAL 
ADENOMAS…………………………………………………………………………………………57 
1.2 KRAS, NRAS, BRAF AND PI3KCA MUTATION ANALYSIS IN MATCHED ADENOMAS AND 
CRC OF THE SAME PATIENTS……………..………...…………………..……………………….60 
2 L1 AND L1-MET HYPOMETHYLATION LEVELS IN COLORECTAL ADENOMAS AND CRCs ……….62 
3 EXPRESSION ANALYSIS AND CHARACTERIZATION  OF L1-CHIMERIC TRANSCRIPTS..……..…...66 
3.1 RNA-SEQ ANALYSYS ON CRCs CHARACTERIZED FOR L1 HYPOMETHYLATION 
LEVELS………………………………………………………………………………………………66 
3.2 IN SILICO CHARACTERIZATION OF THE L1-MET TRANSCRIPT………………………….…69 
3.3 HIGH LEVELS OF MET AND L1-MET TRANSCRIPTS IN HYPOMETHYLATED CRCs……...71 
3.4 HIGH LEVELS OF MET AND L1-MET TRANSCRIPTS IN HYPOMETHYLATED 
COLORECTAL ADENOMAS……………………………………………………………………….72 
4 CORRELATION BETWEEN CLINICO-PATHOLOGICAL AND MOLECULAR ANALYSYS IN 
        SPORADIC ADENOMAS ADENOMAS…………………………...…………………………………………..75 
        
SECOND PART    
5 CORRELATION BETWEEN rs1800734 ALLELES AND MLH1 METHYLATION IN NORMAL 
COLORECTAL SAMPLES……………………………………………………………………………………...77 
6 CORRELATION BETWEEN rs1800734 ALLELES, MLH1 METHYLATION AND MLH1 EXPRESSION IN 
MSI CRCs………………………………………………………………………………………………………...79 




























































1. COLORECTAL CANCER (CRC) 
 
1.1 EPIDEMIOLOGY AND NATURAL HISTORY  
Colorectal cancer (CRC) is the third most common tumour in men and the 
second in women, accounting for 10% of all tumour types worldwide. Incidence is 
higher in males (ratio: 1.4) and for both genders there is a 10-fold difference in 
incidence between several regions. With 608000 deaths estimated each year (about 
8% of all cancer deaths), CRC is the fourth most common cancer-related cause of 
death in the world. However, mortality has declined progressively in many Western 
countries: this can be attributed to cancer screening programs, removal of adenomas, 
early detection of cancerous lesions and availability of more effective therapies, 
chiefly for early stage disease (1). 
CRC results from the accumulation of genetic and epigenetic alterations, as 
well as biochemical changes in the macro- and microenvironment, which lead to the 
transformation of normal colonic epithelium into benign adenomas and eventually 
adenocarcinoma, known as the adenoma-carcinoma sequence (2-3).                             
The earliest identifiable lesion of the colonic mucosa is the aberrant crypt focus 
(ACF), characterized by histological features including darker staining, raised 
appearance, and crypt size at least three times larger than adjacent normal mucosa (4). 
Individual cells in ACF are morphologically normal, however the thickened layer of 
cells within crypts leads to crowding and mucosal folding. A subset of these 
microscopic mucosal abnormalities are believed to be the precursors of CRC. Some of 
these lesions show mutations in APC or KRAS or BRAF genes and have increased 
expression of proliferative markers (5-8).  
Polyps are benign gland-forming mucosal projections, which can be 
categorized as adenomatous or serrated. Adenomatous polyps, or adenomas, may be 
tubular, tubulovillous, or villous adenomas (9-10).  
The serrated pathway is distinct from the conventional adenoma-carcinoma pathway, 
characterized by serrated architecture of the epithelial compartment (9,11). 
 Hyperplastic polyps are the most common type of serrated lesion and are generally less 









1.2 RISK FACTORS 
It is well known that the risk of CRC is associated with personal predisposing 
features or environmental factors (13). The most significant contributory agents 
include: 
 genetic factors, indeed, the greatest risk factor for CRC is family history (14).        
Several hereditary CRC and polyposis syndromes have been characterized. The 
hereditary CRC syndromes are classified based upon the clinical presence or absence of 
colonic polyps as a major disease manifestation and the presence of known causative 
genetic mutation (15). However, only 5-10% of CRCs can be attributed to germline 
mutations in highly penetrant genes associated with hereditary CRC syndromes, leaving 
a proportion of CRC risk that may be associated to familial predisposition due to 
germline variants in currently unidentified genes. Epidemiological studies demonstrated 
that an individual’s risk of CRC doubles if one first-degree relative also has CRC, and 
quadruples if two first-degree relatives are affected by CRC (16-17). Currently, it is 
widely accepted that the accumulation of a number of low-risk, low-penetrance alleles 
and a combination of genetic and environmental factors may contribute to significant 
CRC risk (18-21); 
 age is considered an important risk factor for sporadic colon cancer: nearly 70% 
of patients with colon cancer are over 65 years of age. CRC is rare before 40 years even 
if data from SEER (Surveillance, Epidemiology, and End Results) and Western 
registries show an increasing incidence in the 40–44 years group (22);  
 chronic disease history: chronic inflammation diseases, such as Crohn's bowel 
syndrome or ulcerative colitis can induce colorectal carcinogenesis and the risk 
increases further with early age at diagnosis of inflammatory bowel disease, duration of 
symptoms and severity of the inflammation. In this context, the gut microbiota and 
dysbiosis situations may have a crucial role (23-25); 
 presence of adenomas: there is a high risk of CRC in individuals whose 
adenomas are not removed (26). These lesions are typically asymptomatic and are often 
found incidentally during colonoscopy performed for unrelated symptoms or for CRC 
screening. Although not all colonic polyps are adenomas and more than 90% of 
adenomas do not progress to cancer, a differential diagnosis that takes into account the 
various types of colorectal polyps and the accurate identification of those that will 
progress to cancer remain challenging. High-risk features of colonic polyps are 







multiple adenomas, lesions that are larger than 1 cm in size, villous or tubulovillous 
histology and high grade dysplasia are considered important risk factors for CRC 
development (10). Some studies only recently suggested that adenomas with somatic 
KRAS or BRAF mutations, might provide information about the risk of developing 
metachronous advanced neoplasia during follow-up for patients diagnosed with polyps 
(27); 
 lifestyle: smoking, environmental factors such as a diet rich in unsaturated fats 
and red meat, excessive alcohol consumption, and reduced physical activity predispose 
to CRC (28-31). Unfortunately, specifically dietary and environmental factors that 
contribute to CRC in Western countries are not particularly well defined, and the 
majority of CRCs arise in people with poorly defined risk profiles.  
 
1.3 SCREENING, STAGING AND PROGNOSIS  
Several screening strategies exist for asymptomatic persons at average risk for 
developing CRC. These strategies have allowed for earlier detection at more curable 
stages and have resulted in reduced mortality rates (32-35). The guaiac fecal occult 
blood test (gFOBT) is a non-invasive procedure able to detect small amounts of blood 
in stool.  
Clinical trials have demonstrated that individuals with positive occult blood tests 
have three to four times higher risk for developing CRC compared to those with 
negative tests (36) and that gFOBT reduced CRC mortality by 15-33% (37-40).  
Actually, gFOBT has low sensitivity for CRC (25-38%) and advanced adenomas (16-
31%) (41). For this reason, the gold standard of examination is colonoscopy, which 
allows for full colonic examination combined with polypectomy in a single session. 
Studies have shown that colonoscopy reduces CRC incidence by 67-77% and CRC 
mortality by 31-65% (42-45). This method has the highest level of sensitivity and 
specificity of any screening method and is the final assessment step of any current 
screening program (46-47). 
The stage at which CRC is diagnosed determines the treatment options and is 
currently the strongest predictor of survival. The tumor-node-metastasis (TNM) is the 
most widely used cancer staging system: T refers to the local extent of untreated 
primary tumour at the time of diagnosis and initial workup; N refers to the status of the 
regional lymph nodes; M refers to distant metastatic disease. Pathological classification 







primary tumour and clinical classification is based on a variety of techniques including 
physical examination, radiologic imaging, endoscopy, biopsy, and surgical exploration 
(48). Using the TNM staging system, the five-year disease-specific survival rate of CRC 
is around 90% for stage I CRCs, 85% for stage II, 70% for stage III, and 10-15% for 
stage IV disease (49-50). 
 


































2. MOLECULAR PATHWAYS IN CRC 
  
 CRC has long been considered a single disease process with shared causality, 
clinical characteristics, and prognosis. Recently, applications of molecular technologies 
coupled with extensive analysis of precursor lesions and hereditary forms of the disease, 
have shown that CRC is a heterogeneous and complex disorder that develops as a 
consequence of accumulation of both genetic and epigenetic alterations. In CRC, there 
are at least three major pathways contributing to instability: chromosomal instability 
(CIN), microsatellite instability (MSI) and epigenetic instability, known as the CpG 
island methylator phenotype (CIMP). The genetic and/or epigenetic alterations common 
to the progression of these three pathways are shown in Figure 1 (51).                                
These three pathways are not always mutually exclusive. About 25% of MSI CRCs 
exhibit chromosomal instability and 12% of CIN tumors have high level of MSI (52). 
CIMP is most often found in MSI positive CRCs, but up to 35% of CIMP positive 
tumors exhibit high levels of chromosomal abnormalities (53-55). The biological 
relevance of these overlapping pathways and their role in prognosis are not yet fully 
understood. 
 
Figure 1. Three major pathways leading to colorectal cancers. (1) Conventional adenoma-carcinoma 
sequence with oncogene (e.g. KRAS) activation and tumor suppressor (e.g. APC, SMAD4 and TP53) 
inactivation, resulting in microsatellite stable (MSS) cancers; (2) Microsatellite instability (MSI) pathway 
with mismatch repair (MMR) protein, resulting in MSI-high (MSI-H) cancers; (3) Serrated pathway with 
CpG island methylation phenotype, resulting in either MSI-H cancers if methylation occurs in MLH1 
promoter or MSS cancers if methylation occurs in tumor suppressor genes. HGD: high-grade dysplasia; 




























The CIN pathway is also known as the adenoma-carcinoma sequence and it 
follows a predictable progression of genetic and corresponding histologic changes. The 
inactivation of the APC gene is the earliest event associated with adenoma formation, 
through the activated Wnt-signaling (56-57). The physiological role of APC is to 
abolish the Wnt signaling cascade when appropriate by binding to a complex of proteins 
including β-catenin, glycogen synthase kinase-3β (GSK3β), and casein kinase 1 (CK1) 
on an axis inhibition protein 1 (AXIN1) scaffold. This is known as the β-catenin 
destruction complex, which facilitates the phosphorylation of β-catenin by GSK3β and 
CK1 leading to its proteasomal degradation, aided by β-transducin-repeat-containing 
protein (βTRCP). Mutations of APC, occurring in >75% of CRC tumours, increase 
transcriptional activity of β-catenin (57-58).   
Alternatively, mutations can occur in β-catenin (CTNNB1) or other Wnt components to 
bring about the same activation (59-60).  
Subsequent KRAS mutations occur in about 10% of adenomas but are observed 
in about 50% of adenomas with high grade dysplasia, whereas deletions (or other 
alterations) of genes in chromosome 18q affect adenoma growth and progression. The 
biallelic loss or inactivation of TP53 and other genetic abnormalities like mutations in 
TGFβR and PIK3CA drive the activation of the adenoma-carcinoma transition (61-62). 
Although according to this multistep model at least 7 distinct mutations are required for 
tumorigenesis, genome-wide sequencing of CRCs have calculated about 80 mutated 
genes per tumor, with less than 15 mutations considered to be true drivers (62). 
Moreover, whether CIN creates the appropriate environment for the accumulation of 

















2.1.1 THE ROLE OF DNA HYPOMETHYLATION IN CRC 
The first-described epigenetic change in human cancer was the global DNA 
hypomethylation in 1983 (63).  However, for several decades, it was almost ignored, 
with attention mainly focused on the hypermethylation of genes that are silenced in 
cancer. 
Different investigations sustain a causal link between DNA hypomethylation and CIN, 
reporting an association between this epigenetic defect and aneuploidy in human 
colorectal cancer cell lines (64), changes in DNA methyltransferase activity and loss of 
imprinting. Moreover, hypomethylation of satellite DNA at the juxtacentromeric 
heterochromatin and chromatin decondensation was observed in cancer cells (65-66). 
This epigenetic event is frequently linked with altereted chromatin structure, changes in 
DNA methyltransferase activity and loss of imprinting. The resultant aberrant 
transcription and chromosomal instability is believed to contribute to disease onset or 












Figure 2.  The figure shows potential causes and consequences of DNA hypomethylation (65). 
 
Global DNA hypomethylation in cancer was mostly associated with repeated 
DNA elements such as Long Interspersed Nucleotide Elements (LINE), and for a long 
time this epigenetic alteration continued to receive rather little attention. Indeed, due to 
the lack of any obvious function, LINE have long been regarded as parasitic 
components of genomes. This view has now been changed for two main reasons: a 
structural and a functional one. First, sequencing of higher eucaryotic DNAs indicated 







whereas protein-encoding genes do not exceed 2% in the human genome (The-
ENCODE-Consortium Nature 2012). Second, LINEs play functional roles during 
various (physiological) and pathological processes (67). In somatic cells, LINE-1 or L1 
(the only active retro-trasposon in humans covering approximately 17% of the entire 
genome) is actively suppressed by several mechanisms that have been recently 
described, namely: i) silencing of L1 activity by DNA methylation (68); ii) binding of 
PIWI RNAs that target L1 transcripts leading their degradation (68); iii) control of L1 
activity by SIRT-6, a chromatin-associated protein that is required for normal base 
excision repair (BER) of DNA damage in mammalian cells (69).  
In several type of cancers L1 are strongly hypomethylated and, due to the 
abundance of these elements in human genome, this is taken as a valid surrogate of 
genome-wide methylation. A large body of evidence supports that global 
hypomethylation involving L1 elements is an important cause of their reactivation in 
cancer (68). In CRC, L1 hypomethylation significantly correlates with various clinico-
pahological and molecular variables. L1 hypomethylation can be found early in 
carcinogenesis since the colonic mucosa from CRC patients has been reported to show 
lower global methylation levels compared with control individuals (70-74). Karyn L et 
al. recently have shown that deletion of Dnmt1 in the adult intestinal epithelium of Apc 
Min/+ mice causes accelerated formation of adenomas and results in acute 
hypomethylation and genomic instability (75). These results confirm the important role 
of DNA methylation in preserving genomic integrity during intestinal tumorigenesis. 
In addition, L1 hypomethylation is inversely correlated with MSI and the CIMP 
phenotype in CRC (76). Moreover it has been associated with more aggressive 
progression of CRC and with CRC familial clustering (77). Taking these findings 
together, LINE-1 methylation level may serve as a potential tumor biomarker for 
prognostication as well as familial cancer risk assessment (78). 
 The tumorigenic function of L1 elements occur by both retrotransposition-
dependent and independent mechanisms. The former may result in chromosomal 
rearrangements and target gene inactivation. The latter can exhert epigenetic regulation 
by generating endo-siRNAs, forming chimeric L1-transcripts (LCT) or changing the 
expression of adjacent genes by providing alternative promoters or splicing sites (79-80) 
(Figure 3). In particular, demethylation of the L1 promoter leads to the activation of 
both sense (SP) and anti-sense (ASP) promoter regions. The SP controls canonical 







neighbouring sequences (68). The role and features of these chimeric transcripts are not 
fully understood, but they represent an emerging mechanism for the regulation of gene 
expression.  
The high number of L1 elements in the human genome could activate many 
illegitimate transcripts. In silico analyses have revealed up to 911 new putative 
antisense chimeric transcripts across the genome, but only a few of these L1-containing 
genes are implicated in cancer (81).  
The MET oncogene is one of the well-known example of these genes, since the 
hypomethylation of L1 sequence in its second intron can drive the transcription of a 
chimeric isoform of the MET gene, i.e. L1-MET (82). Interestingly, L1-MET was 
reported to be a negative regulator of canonical MET expression in vitro (83). 
Conversely, there are recent reports describing that increased MET protein levels in 
CRC and in hepatocellular carcinomas are associated with a higher transcription levels 
of L1-MET mRNA (84-85).  
The biological roles for L1-MET mRNA expression seem controversial, however, these 
studies suggest that the biological role of L1-MET is cellular context dependent.                                                                                                                  
Finally, methylation of the MET gene plays an indispensable role modulating its 
expression in some cancers. It has been shown that the MET gene is hypomethylated 
and thus overexpressed in pancreatic ductal adenocarcinomas (PDAC). Importantly, the 
hypomethylation status of the MET gene is correlated with low overall survival and 

















Figure 3. Representation of potential pathogenic functions of L1 in cancer.  
(a) L1 insertion mediated inhibition of host gene transcription: L1 can potentially act to slow RNA pol II 
elongation, dissociate it from the template, or induce premature termination of transcription. (b) L1 
insertion–mediated oncogene activation: the ASP within L1 inserted antisense to gene MET serves as a 
transcription start site to drive MET expression. (c) 3’transduction: downstream sequence of L1 3’ end is 
transcribed together with L1 and the resultant LCT is reverse-transcribed and integrated into a new locus 
by L1 retrotransposition machinery. (d) L1-mediated formation of processed pseudogenes: mature mRNA 
(lacking introns) is reverse-transcribed and integrated into a new locus by the L1 retrotransposition 
machinery to generate processed pseudogenes that lack introns and are punctuated by a 3’ poly-A tail. (e) 
Functions of LCTs in cancer: ASP within L1 drives the transcription of LCT that runs antisense to 
upstream TFPI-2 gene. The expression of TFPI-2 is inhibited by this LCT (upper). HBx from the HBV 
genome drives LCT that is transcribed partially from HBx and partially from L1 sequence. This LCT 
functions as an oncogenic long noncoding RNA that can activate Wnt/Functions of LCTs in cancer: ASP 
within L1 drives the tranare shown for gene MET and TFPI-2. ASP, antisense promoter; HBV, hepatitis B 
virus; L1, long interspersed nuclear element-1; LCT, L1 chimeric transcript; ORF1p, protein encoded by L1 















2.1.2 DNA HYPOMETHYLATION AND OXIDATIVE STRESS 
It has been considered that elevated levels of reactive oxygen species (ROS), 
down regulation of ROS cleaners, and antioxidant enzymes are related to various 
tumors (88). Besides, high levels of ROS contribute to tumor development through both 
genetic and epigenetic mechanism.  
Published studies have reported that DNA global demethylation is associated with 
oxidative DNA damage and several mechanisms have been proposed (89-90).                       
ROS can directly trigger the oxidation of macromolecules within the cell and DNA 
oxidation involves in a variety of damaged sites.  
The most common studied oxdidative DNA lesion was the 8-Oxo-2'-deoxyguanosine        
(8-OHdG) that nowadays is widely used as a biomarker for oxidative stress.  
8-OHdG can also exert an influence on the DNA methylation of nearby cytosine and its 
presence negatively affect adjacent sites methylation (91-92).  
In this context, Turk et al. made an additional discovery describing how the oxidative 
damage on the nascent strand could suppress DNA methylation through the target 
cytosine one or two base pairs away from the damaged guanine (93). 
Moreover, in an oxidative stress condition with decreased availability of                            
S-adenosylmethionine, a depletion of the methyl pool has been shown to cause DNA 
hypomethylation in folate-deficient models (94). 
On the other hand, DNA methylation may also influence the mutagenic effect of 
ROS. Notably, 8-OHdG may function as a premutagenic base instructing DNA 
polymerases to incorporate dAMP, a mismatch pairing inducing G→T transversions 
(95).                   
Thus, the methylation of Cyt 5′ to 8-OHdG may interfere with efficient repair of this 
lesion, which partially explains why not only C, but also G in CpG dinucleotides are a 
hot spot for mutations (96).  
8-OHdG is repaired by 8-oxoguanine-DNA glycosylase (OGG1) and methylation of the 
adjacent cytosine abolished stimulation of OGG1 by repair endonuclease APEX1 (97). 
Moreover, the exonuclease activity of APEX1 may remove mCyt 5′ to 8-OHdG, 
providing an intriguing possibility for DNA demethylation coupled with oxidative 
damage repair. 
Finally, other types of oxidative damage could also contribute to DNA 
demethylation. 5-hydroxymethylcytosine (5hmC) is the result of the hydroxylation of 







hydroxylation involved in more than 90% reduction in cytosine methylation and these 
results suggested that DNA methylation could reduce in subsequent rounds of cell 
division (98). Thus oxidative damage may trigger perturbation.  
Additionally, through repair pathways, which considered being responsible for active 
demethylation in undividing cells, the incorrectly hydroxylated 5mC could be returned 
to unmethylated cytosine (99). 
 
2.2 MSI 
About 15% of sporadic CRCs arise from MSI pathway that is associated with 
inactivation of DNA mismatch repair (MMR) proteins, leading to mutation 
accumulation. The MMR machinery consists of a family of enzymes (MLH1, MLH3, 
MSH2, MSH3, MSH6 and PMS2) with the capability of recognizing and repairing 
base-base mismatches or insertion-deletion loops (IDL) generated by DNA replication 
errors acquired during the S-phase of the cell cycle (100). MSI in sporadic CRC is 
mainly caused by DNA methylation of the cytosine and guanine (CpG)-rich promoter 
sequences of MLH1 that causes transcriptional repression and loss of gene function 
(101-102).  
There is a substantial body of literature about the use of MLH1 methylation 
and/or MSI as a biomarker in the classification of CRC. However, the biological 
mechanisms underlying the methylation have not been investigated in detail until 
recently. Fang et al. have demonstrated in cancer cell lines that BRAF oncogenic 
mutations mediate the CpG island methylation phenotype (CIMP) resulting in 
hypermethylation at MLH1 and other CIMP marker genes, via the transcriptional 
repressor MAFG (103). 
Typical for MSI tumours are frameshift mutations in specific genes such as         
b-catenin, TGFbRII, BAX (104-105). In MSI tumorigenesis, serrated adenomas are most 
common and may transform into carcinoma without a component of adenomatous 
dysplasia (106). However, traditional adenomas may also be observed in MSI pathway.                    
It is well-known that MSI sporadic CRCs display distinct clinico-pathological features 
such as proximal colonic site, mucinous or signet ring cell type, poor differentiation, 
presence of infiltrating lymphocytes, frequent BRAF mutations and fewer KRAS and 
TP53 mutations (107).  
MSI tumours are also associated with larger tumour size and more favourable 







CRCs respond poorly to commonly used chemotherapy, such as 5-fluorouracil but are 




A third pathway through which CRC progresses is the CIMP (111-113). It 
consists of the aberrant hypermethylation of CpG dinucleotide sequences localized in 
the promoter regions of tumor suppressor genes, causing their loss of expression. The 
mechanisms that underlay aberrant DNA methylation in cancer cells have been well 
studied in the last years and several data suggest that DNA methylation may be an early 
event in the development of CRC (114). Most CpG islands lack methylation in normal 
colon mucosa but during CRC initiation and progression, specific hypermethylation 
events are frequent and affect several signaling pathways, including Wnt, Receptor 
Tyrosine Kinases, NOTCH, TP53, PI3K, Retinoic Acid, and IGF as well as other 
pathways involved in cell cycle regulation, transcription regulation, DNA 
repair/stability, apoptosis, adhesion angiogenesis, invasion and metastasis, axon 
guidance, transmembrane glycoproteins, peptide hormones, and chromatin organization 
(115). 
CIMP is found in approximately 20%–30% of CRC and it was reported that 
clinical features of CIMP CRCs are often similar to those associated with MSI (116). 
Interestingly, the precursor lesions of most of CIMP CRCs are believed to be sessile 
serrated adenomas (SSA), exhibiting both BRAF mutation and high level of CpG island 
methylation (117). Most of these lesions, particularly those in the proximal colon, have 
been so far under-recognized and missed during colonoscopy, qualifying these lesions 
as the main cause of interval cancers. It is estimated that 10%-20% of CRCs evolve 















3. HEREDITARY COLORECTAL CANCER SYNDROMES 
 
As reported above, about 5 to 10% of CRCs can be attributed to inherited 
susceptibility syndromes (118–119). These hereditary syndromes are broadly classified 
upon the clinical presence or absence of multiple colorectal polyps into two categories.   
Here, we focused on the three most frequent forms of hereditary CRC currently 
managed in the diagnostic routine of  Genetic Counseling Service: MUTYH-associated 
polyposys (MAP) and familial adenomatous adenomatous polyposis (FAP) versus 
Lynch syndrome (LS). 
 
3.1 MUTYH-ASSOCIATED POLYPOSIS (MAP) 
In 2002, Al-Tassan et al. described for the first time MAP syndrome, a recessive 
form of polyposis associated with biallelic mutations of MUTYH gene (120)                    
(OMIM 604933). This gene is located at chromosome locus 1p34.1, is 11.2 kb long and 
has 16 exons.  
The MUTYH protein is a base excision repair (BER) glycosylase involved in the repair 
of one of the most frequent and stable forms of oxidative damage, oxidation of a 
guanine leading to 8-OHdG. When an oxoG:A mismatch is present in the                  
DNA-template,  in the next round of replication a G:C to T:A transversion will occur. 
MUTYH recognizes an oxoG:A mismatch and excises the undamaged adenine base 
using a base–flipping mechanism. DNA polymerases can subsequently restore an 
oxoG:C pair that can be acted upon by another BER-glycosylase, OGG1, to replace the 















Figure 4.  Pathways for the removal of 8-OHdG in human cells. 
 
To date, 308 unique sequence variants for the MUTYH gene have been reported 
in the Leiden Open Variation Database (LOVD) of the InSiGHT (International Society 
for Gastrointestinal Hereditary Tumours). These are predominantly missense mutations, 
but also small deletions and duplications may be observed. 
In Caucasian populations, a biallelic status for the hot spot mutations p.Y179C and/or 
p.G396D is reported in up to 70% of MAP patients. Furthermore, 90% of the western 
MAP population carries at least one of these mutations (124). 
The MAP phenotype resembles that of APC-linked attenuated familial 
adenomatous polyposis (AFAP) with the appearance of a limited number of adenomas               
(generally 30–100) in the fourth to fifth decade of life. However, unlike AFAP, 
approximately 60% of MAP patients show colorectal cancer at presentation (125).  
MAP carcinogenesis displays peculiar molecular features that characterize disease 
progression; CIN is detectable during the early stages in MAP tumours (126) and the 
somatic molecular fingerprint of this syndrome is an excess of KRAS c.34G>T 
transversions, due to the failure of the impaired MUTYH to repair the mismatches 
induced by the 8-oxoG variant base (127). 
Since oxidative stress occurs in various cell types, MUTYH inactivation can be expected 
to predispose not only to intestinal, but also to extraintestinal lesions. Key extracolonic 







A multicenter study showed also that the incidence of extraintestinal malignancies 
among MAP cases is almost twice that of the general population, with a significant 
increase in the incidence of ovarian, bladder, and skin cancers, and a trend of increased 
risk of breast tumors (128). 
Regarding clinical management of MAP patients, the genetic testing of MUTYH 
in patient with phenotypic features suggestive of this disease is essential in planning for 
the surveillance needs in the extended family. Indeed, there seems to be a consensus in 
the literature to suggest surveillance in MAP patients, according to AFAP protocols. 
Colonic surveillance should start at age 18–20 years and gastroduodenal surveillance at 
age 25–30 years (129). 
 
3.2 FAMILIAL ADENOMATOUS POLYPOSIS (FAP) 
FAP is an autosomal dominant disease with almost complete penetrance by age 
of 40 years (ORPHA 733; OMIM 175100). In 1991, germline mutations in the APC 
gene were identified as the cause of FAP that is characterized by the development of 
hundreds to thousands of premalignant adenomas in the gastrointestinal tract, mostly in 
the colon and the rectum, at a young age (130). 
APC is a gene with 15 exons located in the long arm of chromosome 5 in band 
q22.2 that encodes a 2843 amino acid protein. More than 4000 different mutations of 
the APC gene causing FAP have been reported in the LOVD database resulting in a 
truncated protein where approximately one third of germline mutations in APC lie 
between codons 1061 and 1309 in the center of the gene (131-132). 
FAP accounts for less than 1% of all CRC cases and affects approximately 1 in 10,000 
people. Patients with FAP develop CRC at an average age of 35 years if left untreated, 
although there are differences within and between families, some of which can be 
explained by specific germline mutations in APC (133). 
 An attenuated form of Familial Adenomatous Polyposis (AFAP) is characterized 
by mutations at the 5’-and 3’ ends of APC gene and the development of less than 100 
polyps, mainly located in the left colon. In AFAP, the average age for the development 
of adenomas and CRCs is older compared to that associated to the classic FAP (134).             
FAP patients frequently develop benign extracolonic lesions including polyps of the 
gastric fundus and duodenum, osteomas, dental anomalies, congenital hypertrophy of 







In addition, several extracolonic cancers occur with a higher incidence in FAP than in 
the general population. These cancers include tumors of the upper gastrointestinal tract, 
liver, thyroid and adrenal gland, pancreas, and brain (135-136). 
Genetic testing is routinely used for detection of FAP. Flexible sigmoidoscopy at 
the age of 10-12 years old is recommended for screening for polyps in APC gene 
mutation carriers. Once polyps are detected, annual colonoscopy for polyp screening is 
recommended and when the polyp burden increases, prophylactic colectomy is offered. 
If the rectum is left, annual endoscopy is needed because of adenoma’s development 
risk. Screening for polyps and adenomas in the upper gastrointestinal tract with 
gastroduodenoscopy is preferred to initiate at the age of 25-30 years, every 1-3 years 
depending on the poly burden (137). 
 
3.3 LYNCH SYNDROME (LS) 
Lynch Sindrome (LS) is the most common hereditary colon cancer syndrome 
with autosomal dominant transmission and high penetrance (80-85%) accounting for 2-
4% of all CRCs (138-139). 
LS is characterized by germline mutations in DNA MMR genes MLH1, MSH2, MSH6 
and PMS2, which cause inability to correctly repair errors occurring during DNA 
replication, especially in the repeat sequences like microsatellites. For this reason, most 
Lynch syndrome tumors arise through the MSI pathway. 
Mutations in these genes not only cause development of CRC but also an 
increased risk of extracolonic cancers including endometrial, ovarian, gastric, small 
bowel, upper urologic tract, pancreatic cancer, hepato-biliary tract and brain (140). 
The LOVD database has collected so far 2360 MMR germline variants; more frequently 
mutated genes are MLH1 (50%) MSH2  (40%), followed by MSH6 (10%) and PMS2 
(less than 5%) (141). 
The germline mutation is present in every cell of these individuals and loss of functional 
MMR occurs when the wild-type allele is inactivated by a somatic mutation, due to 
different genetic mechanisms (deletion, mitotic recombination, point mutation, genetic 
conversion, loss of heterozygosity), or by an epimutation even in absence of germline 
mutation in MMR genes (142).  
Many criteria have been proposed for identifying patients with Lynch syndrome, 







affected family members. The syndrome is clinically defined by the Amsterdam and the 
revised Bethesda guidelines for selecting patients for further genetic analysis (143). 
The main clinical feature is early age of diagnosis and the occurrence of multiple 
tumours. The average age at diagnosis of CRC in Lynch syndrome is between 42 and 61 
years, which is lower than the general population (144).  
Periodic examination by colonoscopy is recommended for detecting CRC in an early 
stage and a 63% risk reduction in CRC development can be achieved reducing the 


























4. IDENTIFICATION OF LOW-PENETRANCE ALLELES 
IN CRC 
 
Over 29,000 Single nucleotide polymorphisms (SNPs) associated with numerous 
traits and diseases have been discovered thus far through genome-wide association 
studies (GWAS) (145). SNPs can exert their influence on disease pathogenesis in a 
variety of ways. If located within a gene a SNP may have direct or indirect 
consequences on the function or structural stability of a protein if it changes the primary 
structure (146). Exonic SNPs resulting in amino acid substitutions, called non-
synonymous SNPs, are the most well characterized genetic polymorphisms. They are 
subject to detection bias and can usually be assayed for their functional effects (147). 
Synonymous exonic SNPs that do not alter protein structure may still affect mRNA 
stability and alter splicing signals (148). SNPs located in introns, promoters, enhancers, 
or any other non-coding regions can also be functionally important through alteration of 
gene regulation. Methodologies are currently being developed for predicting the 
function of SNPs located in introns or regulatory regions (149-150). 
SNPs may also disrupt or create CpG dinucleotides, causing altered methylation 
patterns (151). 
It is likely that the accumulation of a number of low-risk, low-penetrance alleles 
contributes to significant CRC risk. 
SNPs identified as being associated with CRC or other disease may be risk-associated 
variants, or modifier variants/alleles. Modifier variants are coding or non-coding 
regulatory elements that interact with the genome, and modifier variants can act 
together to modulate a phenotype in complex diseases (152). 
30 published studies established an association between SNPs and colorectal cancer, for 
















4.1 THE ROLE OF SINGLE NUCLEOTIDE POLYMORFISM rs1800734 OF 
MLH1 PROMOTER IN PREDISPOSITION TO CRC 
 Several CRC susceptibility SNPs have been identified within MMR genes 
included MLH1. 
The importance of MLH1 in CRC and its propensity for hypermethylation has been 
known for some time (154), however there is few detailed analyses of how, where and 
when MLH1 epimutations occur during sporadic carcinogenesis, and no good 
explanation for why somatic MLH1 mutations are very rare. 
In 1999 Deng et al. correlated MLH1 hypermethylation with the absence of gene 
expression and examined the methylation status of its promoter in four regions: A 
region (from -711 to -577, containing 23 CpG sites), B (from −552 to −266, 19 CpG 
sites), C (from −248 to −178, 8 CpG sites), and D (from −109 to +15, 7 CpG sites) 
(155). They finally concluded that methylation status of CpG sites in region C provided 
the best correlation and prediction of MLH1 expression differently from regions B and 
D while methylation in region A seemed not to be critical in silencing the gene 
expression. 
 A common G/A single nucleotide polymorphism (SNP),                            
rs1800734 (MLH1-93 G>A), is located in the core of the promoter of MLH1, 93 bases 
upstream of the transcription start site in a region that is required for maximal 

















This SNP was initially analysed as a candidate for CRC susceptibility and has since 
then been assessed in a number of data sets (157-161).  
Indeed, the AA homozygotes and AG heterozygotes have an increased risk of MSI CRC 
compared with GG homozygotes. 
Published studies have found associations between rs1800734 genotype, MLH1 
methylation and protein absence in cancers (159-161). By contrast, there are very few 
information on the mechanism of CRC susceptibility caused by rs1800734 genotype. 
Data such as associations between SNP alleles and MLH1expression or methylation in 
normal tissue or MSS cancers are absent or deficient. 
Two different studies have performed pilot luciferase reporter assay to investigate the 
allele-specific effects of rs1800734 on transcription and both groups have found the risk 
allele to be associated with significantly lower MLH1 mRNA expression, despite the 
reporter system lacking the endogenous chromatin environment and, most likely being 
essentially unmethylated. The findings indicate that in vitro differential expression is 
likely to be driven primarily by transcription factor binding rather than methylation, 
suggesting dynamic interplay between transcription and methylation as a potential 
mechanism of rs1800734-associated MLH1 repression (162-163). 
There is evidence that binding of the transcription factor TFAP4 (AP-4) is modified by 
rs1800734 (164). However, Liu et al. detected no difference in MLH1 allele-specific 
expression as a result of TFAP4 allelic bias. They showed instead an effect on the 
expression of the gene encoding the protein kinase DCLK3 and long range chromatin 
interactions between rs1800734 and the DCLK3 promoter.  
 Although the majority of DNA methylation research focused on CpG islands 
within MLH1 promoter, Savio et al. have observed recently a modulation of transciption 
factor binding and differential DNA methylation patterns at the MLH1 shore in blood 
mononuclear cells (PBMC) DNA of CRC cases and controls in association with variant 
rs1800734 genotype.  
Therefore, these data suggested a dynamic genotype-associated epigenetic regulation of 








Figure 6.  Schematic model of DNA methylation at the MLH1 CpG island and shore. In PBMCs and 
normal colorectal tissue (left panel) the MLH1 shore incurs hypomethylation in association with variant 
SNP genotype of rs1800734. No methylation is present at the CpG island in these DNA sources. In 
colorectal tumour  (right panel), DNA methylation at the CpG shore loses its association with rs1800734 
























































The operative work of my PhD training in Experimental and Traslational Medicine has 
been carried out at the laboratory of molecular pathology of the Anatomic Pathology 
Unit of Varese Hospital and at laboratory of Cancer Biology of the Wellcome Trust 
Centre for Human Genetics in Oxford. 
 
Therefore, the thesis can be divided in two parts. 
 
 In the first part we focused on the aberrant hypomethylation of DNA and the 
main aims were: 
1. To investigate the early genetic and epigenetic features in colorectal 
premalignant lesions characterized by oxidative DNA damage and to assess their 
potential involvement in driving colorectal carcinogenesis. To this purpose, we 
analyzed a cohort of colorectal adenomas and carcinomas derived from MAP subjects, 
sporadic adenomas and carcinomas and a control set of FAP/AFAP for their L1 and        
L1-MET methylation status and for their mutational profiles; 
 
2. To characterize the L1-MET transcript induced by L1 hypomethylation. 
 
In the second part we studied the promoter of MLH1 in order to elucidate the 
relationship between methylation and risk/protective allele at rs1800734 during CRC 
progression. 
In detail, the specific aims were the following: 
  
1. To analyze in a cohort of normal colorectal samples and CRCs the associations 
between rs1800734 alleles, MLH1 mRNA expression and MLH1 methylation; 
 

















































1. PATIENTS AND SAMPLES 
 
 We studied 168 formalin fixed and paraffin embedded (FFPE) adenomas and 26 
CRCs cancers collected in the last 20 years from the files of the Department of 
Pathology of the Ospedale di Circolo-University of Insubria, Varese, and from the 
archives of the Pathology Unit of Candiolo Cancer Institute (FPO-IRCCS).  
Overall we analyzed 52 adenomas and 11 carcinomas from 18 MAP patients carrying 
different biallelic MUTYH germline mutations (patients M1-M18; 9 females, 8 males; 
median age of 47 years, range 39-79 years), 36 adenomas from 17 FAP/AFAP  patients 
with different APC germline alterations (patients F1–F17; 10 females and 7 males; 
median age of 37 years, range 21–61 years) and 80 sporadic adenomas from 62 
individuals (28 females, 34 males; median age of 66 years, range 44-84 years) (Table 1 
and Supplementary Tables S1-S3). 
After genetic counseling, MAP and FAP/AFAP patients underwent MUTYH and APC 
germline mutation analysis. Germline mutations are reported in Supplementary Table 
S1-S2). Seventeen out 36 MUTYH mutations were the most common pathogenic 
p.Y179C and p.G396D; 11 were truncating and 8 were missense whose pathogenicity 
was checked in the Leiden Open Variation Database (http: //www.lovd.nl/MUTYH). 
Regarding APC mutations, all were truncating (N=14) expect for three large 
rearrangements: a exon 2 deletion, a whole gene deletion and a translocation t(5;7) 
(q22;p15).  
In most of MAP and FAP/AFAP cases, multiple adenomas from the same patient were 
investigated. In particular, for six MAP patients, we could analyze adenomas and 
carcinomas derived from the same six subjects (cases M1, M6, M16, M18 with 
adenomas and one carcinoma each, and cases M4 and M9 with adenomas and two 
carcinomas each), for nine MAP patient only adenomas (M2, M3, M5, M7, M8, M10, 
M12, M14 and M15) and in three patients only carcinoma samples (M11, M13 and 
M17) (Supplementary Tables S4).  
For the sporadic cases, we enrolled those individuals who had undergone the 
endoscopic screening without a previous report of adenoma detection. In addition, 
familiarity for polyposis was excluded according to their clinical history by interview.  
In details, in this subset we distinguished two different groups of cases: 1) 56 sporadic 







follow-up of ten-years; 2) 24 sporadic adenomas (S-AdsC) from 17 individuals who 
developed a CRC at least one year after polyp removal. For 15 of these patients we 
could also analyze for comparison the matched CRC (Supplementary Tables S3, S5). 
 The histopathological revision was performed by an expert pathologist 
according to the WHO classification of CRCs (167). 
High-grade dysplasia was observed in 8% of MAP adenomas, 6% of FAP/AFAP 
adenomas, 24% of sporadic adenomas, respectively. The remaining cases showed low-
grade dysplasia. A tubular histology was observed in 91 adenomas (32 MAP, 27 
FAP/AFAP and 32 sporadic polyps), while 73 samples were tubulovillous (20 MAP, 9 
FAP/AFAP and 44 sporadic polyps) and 4 villous (Supplementary Tables S1-S3).  
Additional clinico-pathological data were collected for sporadic samples and included: 
site, size and number of sporadic adenomas at diagnosis.  
 




Legend: MAP, MUTYH-associated-polyposis; FAP/AFAP, classical/attenuated adenomatous  
polyposis; V, villous adenoma; TBV, tubulovillous adenoma; TB, tubular adenoma;          










SPORADIC**   
PATIENTS 18 17 62 
Male 9 7 34 
Female 9 10 28 
Mean age 
(min-max) 
47 37 66 
(39-79) (21-61) (44-84) 
 
Adenomas   Adenomas  SAds SAdsC  




V 0 0 0 4 
TV 20 9 36 8 
TB 32 27 20 12 
Dysplasia 
   
  
Low 47 33 43 18 







2.  GENE MUTATIONAL ANALYSIS 
 
 All the 168 adenomas and the 26 CRCs (11 MAP and 15 sporadic cases) were 
analysed for mutations in KRAS (NM_004985.4/LRG_344), NRAS 
(NM_002524.4/LRG_92), BRAF (NM_00433.4/LRG_299), and PIK3KA 
(NM_006218.2/LRG_310) genes using the Sequenom MassArray system (Diatech 
Pharmacogenetics, Jesi, Italy), based on matrix-assisted laser desorption/ionization 
time-of-flight mass spectrometry (MALDI-TOF MS). This analysis was performed 
using the Myriapod Colon Status Kit (Diatech Pharmacogenetics) that includes a series 
of PCR assays designed to interrogate a total of 153 non-synonymous hotspot mutations 
in the four genes. This method is based on primer extension and offers two levels of 
specificity. First, a locus-specific PCR reaction, followed by a locus-specific primer 
extension reaction (iPLEX) in which an oligonucleotide primer anneals immediately 
upstream of the polymorphic site being genotyped (Figure 7) 
This system is particularly suitable for diagnostics use for the minimal amounts of 
















Figure 7.  Workflow of mutation analysis using Sequenom MassArray system. 
Through the use of MALDI-TOF MS, the mass of the extended primer is determined. 







polymorphic site of interest. Sequenom supplies software (SpectroTYPER) that 
automatically translates the mass of the observed primers into a genotype for each 
reaction. Briefly, sequenom analysis was done performing 5 µl PCR reaction mixture 
containing from 10 to 20 ng of DNA (Table 2). After PCR, terminal nucleotides were 
dephosphorylated by Shrimp Alkaline Phosphatase (SAP) reaction (Table 3) and this 
step was followed by the iPLEX single base extension reaction (Table 4).  
The extension products (analytes) were desalted using clean resin and spotted in 
nanoliter volumes onto a matrix-arrayed silicon SpectroCHIP with 96 elements using 
the MassARRAY Nanodispencer (Diatech Pharmacogenetics). The chip is placed into 
the mass spectrometer and each spot is then shot with a laser under vacuum by the 
MALDI-TOF method. A laser beam serves as desorption and ionization source in 
MALDI mass spectrometry. Once the sample molecules are vaporized and ionized, they 
are transferred electrostatically into a time-of-flight mass spectrometer (TOF-MS), 
where they are separated from the matrix ions, individually detected based on their 
mass-to-charge (m/z) ratios, and analized. Detection of an ion at the end of the tube is 
based on its flight time, which is proportional to the square root of its m/z. 
 
Table 2. PCR reaction mix and thermic profile. 
 
Reaction mix   95°C 120''  
Water  1,3 µl  95°C 30''  
10x PCR Buffer 0,5 µl  56°C 30'' X 45 
MgCl2  0,4 µl   72°C 60''  
dNTP Mix  0,1 µl  72°C 300''  
Primer Mix  0,5 µl  4°C 300''  
PCR Enzyme  0,2 µl  10°C Hold  
DNA  2 µl     














Table 3.  SAP reaction mix and thermic profile. 
 
Reaction mix   37°C 2400'' 
Water  1,53 µl  85°C  300'' 
SAP buffer  0,17 µl  4°C 300'' 
SAP enzyme  0,3 µl  10°C Hold 
Total volume 2 µl    
 
Table 4.  IPLEX reaction mix and thermic profile. 
 
Reaction mix   94°C 30''  
Water  0,56 µl  94°C 5''  
Buffer Plus  0,20 µl  52°C 5'' X 40 
Termination mix 0,20 µl  80°C 5''  
Thermosequenase 0,04 µl  52°C 5''  
Primer Mix  1 µl    X 5 
Total volume 2 µl  80°C 5''  
    72°C 180''  
    4°C 300''  
























3. L1 AND L1-MET METHYLATION STUDY IN 
HEREDITARY AND SPORADIC ADENOMAS BY 
BISULPHITE PIROSEQUENCING ANALYSIS 
 
 The methylation status of global and local L1 was evaluated by bisulfite-PCR 
and pyrosequencing in 15 samples of histologically normal colonic mucosa derived 
from healthy individuals obtained from the files of the Department of Pathology of 
Ospedale di Circolo-University of Insubria and in all MAP, FAP, sporadic adenomas 
and MAP and sporadic carcinomas. 
Bisulfite modification of genomic DNA (300 ng) was performed with an EpiTect 
Bisulfite Kit (Qiagen, Hilden, Germany) according to the manufacturer’s 
recommendations. 
Bisulfite-modified DNA was amplified and sequenced by using L1 and L1-MET 
primers and protocol reported below (Table 5, Table 6 and Table 7). 
Pyrosequencing was carried out with PyroGold reagents on a PyroMark Q96 ID system 
(Qiagen, Hilden, Germany). Pyrogram outputs were analyzed by the Pyromark Q24 
software using the Allele Quantification software (Qiagen, Hilden, Germany) to 
determine the percentage of methylated alleles at each CpG site examined.  
Global L1 assay was designed toward a consensus L1 sequence (GenBank accession 
number M80343.1) and allowed to quantify the percentage of 5-methylated cytosines 
(%5mC) in four consecutive CpG sites as previously reported (Figure 8) (168).  
 Intragenic levels of L1 methylation were analyzed using the L1-MET assay: the 
forward PCR primer was located inside the L1 promoter, and the reverse primer was 
designed within the MET gene intron between exons 2 and 3. The sequencing primer is 
immediately upstream a sequence that includes three CpG sites whose mean 
methylation percentage was quantified (GenBank accession number: NG_0089961). 
Fully methylated and unmethylated DNA (Millipore, Billerica MA, USA) were used as 
positive and negative controls in each experiment. Reproducibility was confirmed by 
analyzing all the samples in duplicate with a maximum of within-sample coefficients of 

















Figure 8. Diagram of the pyrosequencing assay used to measure L1 promoter methylation. Arrows 
indicate the sequence and the position of the primers used for the bisulfate PCR and pyrosequencing. The 
percentage of 5-methylated cytosines was measured in four consecutive CpG sites. 
 
Table 5. Primer sequences of LINE-1 and L1-MET pyrosequencing analyses. 
 
 Primer sequence 
L1 Fw 5’-gagttaggtgtgggatatagt-3’ 
Rev 5’-biot-caaaaatcaaaaaattccctttcc-3’ 
Seq-5’-agttaggtgtgggatatagtt-3’ 





Table 6. L1 reaction mix and thermic profile. 
 
Reaction mix   
 
   95°C 3’   
Buffer 10 µl 
 
95°C 25’’   
MgCl2 3 µl 
 
50°C-40°C 25’’ X 40 (TD )   
dNTPSs 5 µl 
 
72°C 25’’   
Primer For 1 µl 
 
72°C 5’   
Primer Back 1 µl 




    
Water MQ 22,25 µl 
    
DNA  5 µl 
    
Final volume 50 µl 











Table 7. L1-MET reaction mix and thermic profile. 
 
Reaction mix   
 
95°C 3’   
Buffer 5 µl 
 
95°C 25’’   
MgCl2 4 µl 
 
67°C-62°C 25’’ X 40 (TD)   
dNTPSs 6 µl 
 
72°C 30’’   
Primer For 1,5 µl 
 
95°C 25''   
Primer Back 1,5 µl 
 
62°C  25'' X 34 
Epitaq Takara 0,25 µl 
 
72°C 25''   
Water MQ 24,25 µl 
 
72°C 3'   
DNA  5 µl 
    
Final volume 50 µl 





























4. MET AND L1-MET EXPRESSION STUDY IN CRCs AND 
PRENEOPLASTIC LESIONS   
 
4.1 RNA SEQ ANALYSIS 
  RNA SEQ analysis of 13 FFPE samples of histologically normal colonic mucosa 
and 32 FFPE CRCs, previously examined in our lab for their clinico-pathological and 
molecular profiles (169), was performed at Laboratory of Molecular Medicine and 
Genomics, University of Salerno. This cohort of sporadic and hereditary CRCs were 
selected because they were stratified into four groups showing significant difference of 
L1 methylation levels: L1>60.1%, L2 (54.1%-60%), L3 (45.8%-54%), L4 (<45.6%).  
Total RNA concentration was measured using Qubit® RNA HS Assay Kit on a Qubit® 
2.0 Fluorometer (Thermo Fisher Scientific Inc., Waltham, MA, USA). Integrity was 
assessed using Agilent RNA 6000 Nano Kit on a 2100 Bioanalyzer instrument (Agilent 
Technologies, Santa Clara, CA, USA) and the percentages of fragments larger than 200 
nucleotides were calculated. RNA sequencing libraries were prepared using TruSeq 
RNA Access library kit (Illumina, Inc., San Diego, CA, USA) according to the 
manufacturer`s protocol. In brief, RNA samples (100 ng total RNA) were fragmented at 
94°C for 8 minutes on a thermal cycler. First strand cDNA syntheses were performed at 
25°C for 10 minutes, 42°C for 15 minutes and 70°C for 15 minutes, using random 
hexameres and SuperScript II Reverse Transcriptase (Thermo Fisher Scientific Inc., 
Waltham, MA, USA). In a second strand cDNA synthesis the RNA templates were 
removed and a second replacement strand was generated by incorporation dUTP (in 
place of dTTP, to keep strand information) to generate ds cDNA. The 3`ends of the 
cDNA were then adenylated to facilitate adaptor ligation in the next step. In a first PCR 
amplification step, PCR (15 cycles of 98°C for 10 seconds, 60°C for 30 seconds and 
72°C for 30 seconds) were used to selectively enrich those DNA fragments that have 
adapter molecules on both ends and to amplify the amount of DNA in the library. After 
validation of the libraries, using Agilent DNA 1000 kit on a 2100 Bioanalyzer 
instrument, the first hybridization step were performed using exome capture probes. 
Before hybridization a 4-plex pool of libraries were made, by combining 200 ng of each 
DNA library. The hybridization was performed by 18 cycles of 1 minute incubation, 
starting at 94°C, and then decreasing 2°C per cycle. Then streptavidin coated magnetic 







hybridization (18 cycles of 1 minute incubation, starting at 94°C, and then decreasing 
2°C per cycle) were required to ensure high specificity of the capture regions. A second 
capture with streptavidin-coated beads were performed, followed by two heated wash 
procedures to remove non-specific binding form the beads. The amplification step was 
performed by 10 cycles (98°C for 10 seconds, 60°C for 30 seconds and 72°C for 30 
seconds). Finally, the libraries were quantitated using Qubit dsDNA HS (High 
Sensitivity) Assay Kit on a Qubit® 2.0 Fluorometer (Thermo Fisher Scientific Inc., 
Waltham, MA, USA) and validated using Agilent High Sensitivity DNA Kit on a 
Bioanalyzer. The size range of the DNA fragments were measured to be in the range of 
200–650 bp and peaked around 270 bp. Libraries were normalized to 2 pM and 
sequenced on a NextSeq500 instrument 2x75 bp (Illumina, Inc. San Diego, CA, USA), 
according to the manufacturer's instructions.  
 For RNA sequencing bioinformatics analysis reads were quality filtered and 
aligned to the human genome hg19 (Homo sapiens Ensembl GRCh37) using STAR 
v.2.5.2a (170). HTSeq (171) was used to compute read counts across each gene 
annotated in UCSC, which were then used as input to R package DESeq2 (172). 
DESeq2 was used to normalize read counts for library size and dispersion followed by 
tests for differential gene expression. Significant differentially expressed genes were 
determined using false discovery rate (FDR) cutoff ≤ 0.05 and at least 1.5-fold change 
between conditions. Functional analyses were performed with Ingenuity Pathway 
Analysis suit (Ingenuity Systems). Finally, TopHat-Fusion (173) was used to detect new 
gene fusion events.  
D 
4.2 CHARACTERIZATION OF L1-MET CHIMERIC ISOFORM  
 After a critical analysis of the literature, we analyzed the structure of the 
protoncogene MET focusing on the L1 sequence residing within its intronic regions, 
between exon 2 and exon 3, in order to elucidate the regulatory mechanism of L1 
hypomethylation-induced chimeric L1-MET isoform activation (Figure 8). 
Previous studies have characterized the chimeric L1-MET isoform, describing the same 
number of exons of MET transcript, i.e. 21, but different exon 1 and exon 2, that are 








In order to analyse by qRT-PCR the expression levels of the two different transcripts, 
distinguishing the physiological variant of MET transcript from the aberrant isoform, we 
designed two primer sets using the sequence alignment software APE. (Table 8). 
The forward PCR primer for MET was located inside the exon 1 and the reverse primer 
was designed within the exon 2. On the contrary, the forward PCR primer for L1-MET 
was located inside the exon 1 of L1-MET that contains also the L1 promoter sequence, 
and the reverse primer was designed within the exon 2 of LI-MET. 
To evaluate the specificity of L1-MET amplicon and confirm the presence of a fusion 
transcript containing the L1 sequence, we sequenced the PCR-amplified products of 
four CRCs after selecting the specific band on 3% agarose gel. These fragments were 
sequenced using BigDye Terminator v1.1 kit (ThermoFisher scientific, Waltham, USA) 
following the protocol reported below (Table 9), purified using DyEx kit (Qiagen) and 
subjected to automated sequencing on ABI PRISM 310 (Applied Biosystems, Foster 
City, Ca). 
  
Figure 9. Schematic illustration of the local LINE-1 sequence in the MET gene between the exons 2 and 
3. The black arrows indicate the LINE-1 sense and antisense promoter. The red boxes represent the first 














Table 8. Primer sequence of MET and L1-MET. 
                                                                           
 Primer sequence 
MET Fw 5’-acttctccactggttcctgg-3’ 
Rev 5’-gcaccaaggtaaacaggagc-3’ 
 




Table 9.  Sequencing reaction mix and thermic profile. 
 
Reaction mix   
 















60°C 4'   
DNA 2 µl 
 
4°C Hold   
Water 3,4 µl 
 
      
Total volume  10 
 
      
sd 
4.3 MET AND L1-MET GENE EXPRESSION ANALYSIS  
 MET and L1-MET expression analyses were possible for 8 specimens of normal 
colonic mucosa, 85 adenomas and 42 CRCs. In details, we analyzed 13 MAP 
adenomas, 16 FAP adenomas, 56 sporadic adenomas, 7 MAP CRCs, 15 sporadic CRCs 
from patients with   
S-AdsC and 20 CRCs previously stratified into the two groups showing the most 
significant differences of L1 methylation levels (namely the two groups: L1>60,1% and 
L4<45,6%) (169). 
Total RNA was extracted from three 8-µm sections of FFPE tissue samples by manual 
microdissection and then automated purification on Maxwell® instrument using the 16 
LEV RNA FFPE Purification Kit (Promega) according to the manufacturer’s 
recommendations. 
Purified RNA was quantified using Qubit® RNA Assay kit and Qubit® 2.0 
Fluorometer. A total of 800 ng of total RNA was reverse-transcribed with random 







Biosystems; Foster City, Ca). The protocol of the retrotranscription and the 
corresponding thermic profile are reported below (Table 10). 
Expression of MET and L1-MET, together with the housekeeping gene β2-
microglobulin (β2-M), was evaluated using the Fast Start Universal Sybr Green Master 
kit (Roche Diagnostic, Mannheim, Germany) and qRT-PCR reactions reported below 
(Table 11) were performed in duplicates in 96-well plates on ABI-Prism 700 detection 
System Instrument using RQ-software (version 1.1, Applied Biosystems). After 
normalization to the endogenous control, the amount of each target gene in tumour 
samples was compared to the normalized expression of the same gene in 8 normal 
colonic mucosae and it was measured by the equation FC 2- Ct  (ie, mRNA fold change 
(fc), where Ct = Ct target genes – Ct of endogenous control and Ct = Ct of 
samples for target gene – Ct of 8 normal colonic mucosae average for the target gene). 
For all the samples included in this study, we observed a very small variation between 
the reactions performed in duplicates with Ct standard deviations lower than the 
acceptable limit of Ct0.5 
 
Table 10. Retrotranscription reaction mix and thermic profile. 
 
Reaction mix   25°C 10' 
10X RT  Buffer 6 µl  37°C 120' 
10X RT Random Primers 6 µl  85°C 5' 
dNTPS Mix 2,4 µl    
Multiscribe Reverse Transcriptase 3 µl    
Rnase Inhibitor 1 µl    
RNA (40 ng/ul) 20 µl    
Water 21,6 µl    
Total volume 60 µl    
h  
Table 11. qRT-PCR reaction mix and thermic profile of MET (a) and L1-MET (b). 
Reaction mix         
Master Mix 8.4 µl  95°C 10'  95°C 10'  
Primer For  0,5 µl  95°C 30''  95°C 30''  
Primer Back 0,5 µl  57°C 45'' X 45 58°C 45'' X 45 
Water 2,6 µl  72°C 1'  72°C 1'  
cDNA 5 µl  95°C 15''  95°C 15''  
Total volume 17 µl  60°C 20''  60°C 20''  









5.   STATISTICAL ANALYSIS  
 
 The statistical analysis was performed using Graph Pad PRISM v.5. Univariate 
comparisons of continuous data were carried out using Student’s t-test and discrete 
variables were compared with χ2 test or Fisher’s exact test. All comparisons were two-

























6. GENOTYPING OF MLH1 PROMOTER rs1800734 BY 
KOMPETITIVE ALLELE-SPECIFIC PCR (KASP)  
 
 The Kompetitive Allele Specific PCR system (KASP™, LGC Genomics, 
Teddington, Middlesex, UK) is a fluorescence-based genotyping variant of PCR that is 
based on allele-specific oligo extension and fluorescence resonance energy transfer 
(FRET) for signal generation. This method is very useful and cost-effective for the bi-
allelic discrimination of SNPs at specific loci. 
The KASP genotyping reaction comprises three components: sample DNA with the 
sequence of interest, KASP assay and the KASP Master Mix (Figure 10). The KASP 
Assay mix is specific to the SNP to be targeted and contains three assay specic non-
labelled primers: two allele specific forward primers plus one common reverse primer.  
In the first and second rounds of PCR, allele-specific primers match the target SNP and 
with the common reverse primer, amplify the target region. Each forward primer 
incorporates an additional tail sequence that corresponds with one of two universal 
FRET cassettes present in the KASP Master mix. In further rounds of PCR, levels of 
allele-specific tail increase and the fluorescent signalling becomes stronger as more 
fluorescent primers are used in the amplification process. 
Following completion of the KASP PCR, reaction mix are read and the data analysed 
using any cluster analysis viewing software. Detected signals are plotted as a graph, 
with samples of the same genotype clustering together.  
The evaluation of the polymorphism A/G within the promoter of MLH1 was performed 
in a 10µl reaction mixture and the oligonucleotides and the thermic profile used are 
reported below (Table 12-13). 
In detail, the genotyping of rs1800734 was performed on the following samples: 
- 33 fresh-frozen normal colorectal biopsies from patients diagnosed without pre-
neoplastic or neoplastic lesions during screening colonoscopy at John Radcliffe 
Hospital in Oxford; 
- 35 FFPE sporadic CRCs previously characterized at Anatomic Pathology Unit in 
Varese for BRAF mutation and for MMR defects. All these tumors were MSI 
CRCs with MLH1 immunohistochemical loss and showed BRAF V600E mutation 





















Table 12.  Genotyping reaction mix and thermic profile. 
 
Reaction mix    94°C 15'  
KASP Master Mix 5 µl  61°C-55 °C 60'' X 10 (TD) 
Primer Mix  0,14 µl  94°C 20''  
Water  3,86 µl    X 36 
DNA  1 µl  55°C 60''  
Total volume  10     
 
Table 13. Primer sequence of rs1800734 allele A and rs1800734 allele G. 
 
 Primer sequence 
rs1800734 Allele A 5’-gaaggtgaccaagttcatgctggatggcgtaagctacagcta-3’ 
 
rs1800734 Allele G 5’-gaaggtcggagtcaacggattggatggcgtaagctacagctg-3’ 
 



























7.    MLH1 METHYLATION STUDY 
 
7.1 MISEQ BARCODED AMPLICON BISULPHITE SEQUENCING OF MLH1 
CpG ISLANDS AND SHORES 
 Amplicon bisulphite sequencing is a highly targeted approach that enables to 
analyze DNA modifications in the form of cytosine methylation in specific genomic 
regions of interest in a large number of samples with high quantitative accuracy. This 
method uses elements of existing methods (bisulfite conversion and region-specific 
PCR amplification) and combines them with simple next-generation library 
construction followed by next-generation sequencing (NGS) using different platforms 
such as MiSeq System Illumina. 
We designed tagged Illumina compatible primers to amplify 10 overlapping regions 
(200-300 bp) covering MLH1 CpG islands and shores in order to perform a 
comprehensive assessment of association between MLH1 methylation and rs1800734 
genotype in 33 fresh-frozen normal colorectal biopsies (Table 12). We also used the 
same system to investigate the alteration of MLH1 promoter methylation induced by 5-
azacytidine (azaC) in CO-115 and SW48 cell lines. 
Bisulfite modification of genomic DNA (300 ng) was performed with EZ DNA 
methylation Kit (Zymo Research) according to the manufacturer’s recommendations. 
Bisulfite-modified DNA was amplified (Table 13) and PCR amplicons were diluted 
1:100 and barcoded with Illumina compatible primers provided by High Throughput 
Genomics Unit at Wellcome Trust Centre for Human genetics (Table 14). 
The barcoded products were then pooled and gel purified (Qiaquick Gel Purification, 
Qiagen) to generate a library for sequencing. The purified library was quantified by 
Qubit Fluorometer 2.0 (Thermo Fisher) and further quantified and assessed using a 
2200 Tapestation System (Agilent). The library was diluted to 2nM with sterile water 
prior to beginning the preparation to run on a MiSeq sequencer (Illumina). 
The MiSeq library preparation was done according to manufacturer’s instructions: 
briefly 5 µl of the 2nM library was denatured using 5 µl of 2M NaOH for 5 minutes. 
This was then diluted to 10pM with HT1 buffer (Illumina). PhiX control DNA 
(Illumina) was denatured and diluted to 10pM as above. The library and PhiX were 
mixed in equal volumes to give a 50% PhiX Spike-In and this step was advised by 







The reagents of a MiSeq v2 500 Nano sequencing kit (Illumina) were defrosted and 
prepared for use according to the manufacturer’s instructions. The library was loaded 
into the indicated well of the cartridge and the run initiated by following the on-screen 
instructions. The output was saved and initial quality control checks carried out using 
the BaseSpace software (Illumina).  
FastQ files were then download and analysed using a bsQC pipeline developed at 
Ludwig Institute for Cancer Research in Oxford (Fig. 11). 
FastQ reads from Basespace (Illumina) were exported and the first step was the 
estimation of conversion’s estimation efficiencies: samples which showed levels of 
unconverted cytosines > 2% were excluded from further analysis. 
Trimming of low quality ends of reads and adapters was performed using Trim Galore, 
a tool which is used for quality control of the input reads (before and after trimming). 
The trimmed reads were mapped to a reference genome using Bismark and the quality 
of the mapped reads was evaluated using Picard tools and SAMtools.  
PCR and optical duplicates were removed using Picard tools and Bismark was used to 
extract the coverage and the percentage of unconverted reads in individual positions. 
Finally, all results were visualised using Imagescale (Matlab) and/or plotted by 
individual CpG per sample.   
  













Table 14. Primer sequence of 10 amplicons covering CpG 









 Primer sequence 
MLH1 long Fw 5’-acactctttccctacacgacgctcttccgatctgggaggttataagagtagggttaa-3’ 
Rev 5’-agacgtgtgctcttccgatctaccttcaaccaatcacctca-3’ 
MLH1 2 Fw 5’-acactctttccctacacgacgctcttccgatctgttattgtttgtttgagaagtgga-3’ 
Rev 5’-agacgtgtgctcttccgatctattcaaaatttcttcacttaaaac-3’ 
MLH1 3 Fw 5’-acactctttccctacacgacgctcttccgatctagttttaagtgaagaaattttgaa-3’ 
Rev 5’-agacgtgtgctcttccgatcttctaaccataatcaacctaactca-3’ 
MLH1 4 Fw 5’-acactctttccctacacgacgctcttccgatctttgttgtttgtagggattttagga-3’ 
Rev 5’-agacgtgtgctcttccgatcttccaaatatcacaaaacaaaaaatcct-3’ 
MLH1 5 Fw 5’-acactctttccctacacgacgctcttccgatcttgtttaggattttttgttttgtga-3’ 
Rev 5’-agacgtgtgctcttccgatcttaacctccttcactcctaaa-3’ 
MLH1 6 Fw 5’-acactctttccctacacgacgctcttccgatctttttaggagtgaaggaggtta-3’ 
Rev 5’-agacgtgtgctcttccgatcttctcaaactcctcctctcc-3’ 
MLH1 8 Fw 5’-acactctttccctacacgacgctcttccgatcttgttattaaagagatgattgagaa-3’ 
Rev 5’-agacgtgtgctcttccgatctcacttacactccaaacaaccctta-3’ 











Table 15.  MLH1 amplicons reaction mix and thermic profile.  
 
Reaction mix    94°C 15'  
Master Mix 12,5 µl  94°C 30''  
Primer For  0,5 µl  56°C 45'' X 44 
Primer Back 0,5 µl  72°C 30'  
Water 10 µl  72°C 10'  
DNA 1 µl  4°C Hold  
Total volume 15 µl     
 
Table 16. DNA barcoding reaction mix and thermic profile. 
 
Reaction mix    95°C 10'  
Buffer 2,5 µl  95°C 15''  
Universal Primer 1 µl  60°C 30'' X 11 
MgCl2 0,75 µl  72°C 1'  
dNTP Mix 2 µl  72°C 3'  
Taq Bioline 1 µl  4°C Hold  
Index Primer 1 µl     
DNA 1 µl     
Water MQ 16,25 µl     
Total Volume 25 µl 









7.2 MLH1 PROMOTER METHYLATION ANALYSIS USING MS-MLPA 
 The SALSA MS-MLPA ME011 Mismatch Repair genes (MMR) Kit (MRC-
Holland, Amsterdam, The Netherlands) was used to perform MLH1 promoter 
methylation analysis on 35 MLH1 immunonegative CRCs previously described 
(Matherial and Methods, Section 6). ME011 Mismatch Repair genes probemix was 
developed to detect aberrant CpG island methylation and included five informative 
probes for MLH1 (3p22.1). The most important methylation region for MLH1 
expression, the Deng C-region, is from -248 nt to -178 nt before the transcription start 
site and the second most important region, the Deng D-region, is from -9 nt to +15 nt 
(Figure 11) (155). 
All MS-MLPA reactions were done according to the manufacturer’s instructions, using 
100-150ng of DNA. The probemix is added to 5 l of denatured DNA and allowed to 
hybridize for 16 hours at 60°C. Subsequently, the sample is divided in two: one half is 
ligated by adding 10 l of ligase-mix, whereas in the other half ligation is combined 
with digestion by adding 10 l of ligation-digestion mix. These samples are incubated 
for 30 minutes at 54°C, then the HhaI enzyme is inactivated by denaturation at 95°C for 
one minute. Since the unmethylated sequences are cut by the restriction HhaI enzyme 
(Promega), this process results in the ligation of the methylated sequences only. Eight 
microliters of the two aliquots are then amplified in a 25 l PCR reaction using Veriti 
thermocycler (Applied Biosystems, Foster City, USA) with the following thermal 
protocol: 33 cycles of denaturation at 95°C for 20 seconds, annealing at 60°C for 30 
seconds and extension at 72°C for 1 minute with a final extension of 20 minute at 72°C. 
In order to assess MS-MLPA reliability two replicates were performed for each sample 
and positive and negative controls using fully methylated DNA (CpGenome Universal 
Methylated DNA, Millipore) and unmethylated DNA (CpGenome Universal 
UnMethylated DNA, Millipore) were included in each MS-MLPA experiment. Aliquots 
of 1.5 l of the PCR reaction were combined with 0.5 l TAMRA internal size standard 
(Applied Biosystems, Foster City, USA) and 13.5 l of deionized formamide. After 
denaturation, fragments were separated and quantified by electrophoresis on an ABI 
310 capillary sequencer and analyzed with GeneMapper 4.0. (Applied Biosystems). 
Values corresponding to peak size (base pairs) and peak height were used for further 







Methylation dosage ratio (MR) was obtained by the following calculation: MR= 
(Px/Pctrl)Dig / (Px/Pctrl)Undig where Px is the peak height of a given probe, Pctrl is the 
sum of the peak heights of all control probes, Dig stands for HhaI digested sample, and 
Undig stands for undigested sample. 
A methylation ratio (MR) for a given gene may range from 0 (0% of alleles methylated) 
to 1.0 (100% of alleles methylated) and threshold values of 0.3 and 0.7 are suggested by 
the manufacturer to consider a locus as hemi-methylated or fully-methylated, 
respectively. 
 
Figure 12. Representation of MLH1promoter region and list of MS-MLPA probes (ME-011 MRC-



















8. MLH1 TRANSCRIPTIONAL ANALYSIS  
 
Total RNA extraction of three 8-µm sections of 9 FFPE normal colonic mucosae 
and 35 FFPE CRCs previously described was performed by manual microdissection 
using a High Pure FFPE RNA Micro Kit (Roche Applied Science, Mannheim, 
Germany) according to the manufacturer’s protocol.  
Purified RNA was quantified using Nanodrop and RNAs were then treated with DNase 
I to degrade residual DNA and complementary DNA (cDNA) synthesis was reverse 
transcribed using the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems) (Table 17). 
Limited-cycle preamplification has been performed before qRT-PCR using the TaqMan 
PreAmp (Applied Biosystems) kit to increase the amount of specific gene targets. 
Expression of MLH1 (Hs00179866, Applied Biosystems) was evaluated using the Fast 
Start Universal Taq Man Probe Master kit (Roche Diagnostic, Mannheim, Germany) on 
the ABI 7900HT cycler (Applied Biosystems) with GAPDH serving as an endogenous 
control (4332649, Applied Biosystems). Each sample was analyzed performing qRT-
PCR reactions in duplicates in 96-well plates (Table 18). 
After normalization to the endogenous control, the relative expression (RE) of MLH1  
transcript in tumour samples was obtained by comparing the normalized expression 
values in tumours versus those observed in normal colonic mucosae, calculated by the 
equation FC=2- Ct , as previously described. 
The same method was applied to investigate MLH1 expression in CO-115 and SW48 



















Table 17. Retrotranscription reaction mix and thermic profile. 
 
 
10 X RT  Buffer 2 µl  25°C 10' 
10X RT Random Primers 2 µl  37°C 120' 
dNTPS Mix 0,8 µl  85°C 5' 
Multiscribe Reverse Transcriptase 1 µl    
RNA (40 ng/ul) 10 µl    
Water 4,2 µl 
   
Total volume 20 µl 
   
 
 
Table 18.  qRT-PCR reaction mix and thermic profile. 
 
Reaction mix         
Master Mix 10 µl  95°C 20''     
Probe  1 µl  95°C 1'     
Water 8 µl  60°C 20'' X 40    
cDNA 1 µl        
Total volume 20 µl        
         























9. DEMETHYLATION ASSAYS BY                                             
5-AZA-2’ DEOXYCYTIDINE 
 
Cell lines were grown in Dulbecco Modified Eagles Medium or RPMI-1640 
supplemented with 10% fetal bovine serum and 1% penicillin streptyomycin (Sigma) at 
37°C in 5% CO2.  
Adherent semiconfluent MSI+ CO-115 and SW48 cells in exponential growth were 
treated with 5uM of 5-Aza-2′-deoxycytidine (AzaC) in a standard medium (AzaC, 
Sigma A3656) for 48 hours (with replenishment of AzaC after 24 hours). AzaC was 
removed, cells washed with PBS, and then cultured in standard medium for 4, 7 and 11 
days. RNA and DNA were extracted simultaneously using the AllPrep kit (Qiagen) and 





























































1. GENE MUTATION ANALYSIS 
 
1.1 KRAS, NRAS, BRAF AND PI3KCA MUTATION ANALYSIS IN 
COLORECTAL ADENOMAS 
 A total of 168 adenomas were analyzed for mutations in KRAS, NRAS, BRAF, 
and PI3KCA genes. The series included 52 adenomas from 18 MAP patients, 36 
adenomas from 17 FAP/AFAP patients and 80 sporadic adenomas from 62 individuals. 
As reported in Material and Methods section, the subset of sporadic lesions was 
specifically selected to include 45 patients with 56 adenomas (S-Ads) without CRC 
development after ten-year follow-up and 17 patients with 24 adenomas (S-AdsC) who 
had developed a CRC at least one year after polyp removal. 
As expected KRAS was the most frequently mutated gene: KRAS mutations were 
more common in MAP (40%, 21/52 cases) and sporadic adenomas (39%, 31/80 cases) 
compared with FAP/AFAP (22%, 8/36 cases); NRAS mutations were observed in only 
8% of MAP adenomas (4 cases) and 1% of sporadic adenomas (1 case) while no 
mutations were found in BRAF and PI3KCA genes (Figure 13A and Supplementary 
Tables S1–S3).  
Taking into consideration all the alterations, MAP and sporadic adenomas were 
significantly more mutated than FAP/AFAP lesions (p=0.02 and p=0.09, respectively).  
In addition, within the subset of sporadic patients, gene mutation frequencies were 
slightly higher in S-AdsC compared with S-Ads (46%, 11/24 cases versus 38%, 21/56, 
respectively) although this difference was not statistically significant.  
The spectrum of KRAS/NRAS mutations was different in the three sets of 
premalignant lesions: 80% of the MAP-mutated adenomas exhibited the c.34G>T 
transversion (p.G12C) in KRAS or NRAS (90% of KRAS mutations and 50% of NRAS 
mutations in MAP adenomas). By contrast, this mispair was totally absent in 
FAP/AFAP and sporadic groups (p<0.0001), which were both enriched for KRAS 

































Figure 13. KRAS/NRAS mutations in the adenoma cohort. (A) Percentage of mutations in MAP 
FAP/AFAP and sporadic adenomas; columns represent the mutation frequencies and KRAS/NRAS 
mutations or wild-type (WT) status are indicated in gray scale as reported as per the legend below. 
(B) Spectrum of KRAS/NRAS mutations in different sets of adenomas; the adenoma groups (MAP, 
FAP/AFAP and sporadic) are reported in pie charts and colours show the different types of KRAS/NRAS 
alterations as per the legend below. 
 
In addition, evaluating both number and type of KRAS/NRAS mutations in multiple 
adenomas of the same patient, 80% of the MAP patients (12/15 cases with adenomas) 
showed at least one mutated polyp compared with 35% of the FAP/AFAP (6/17 cases) 
(p=0.02) (Figure 14A-B). As expected, 10 out of 15 MAP patients exhibited one or 
more KRAS/NRAS p.G12C-mutated lesions (Supplementary Table S1).  
Finally, considering the cohort of patients with sporadic adenomas, 23% (14/62 cases) 












































we observed that 64% of patients (9/14 cases) exhibited at least one mutated adenoma 
(Figure 15A-B).  
 KRAS/NRAS alterations were found in both tubular and tubulovillous MAP 
adenomas. However, MAP adenomas were more frequently mutated than FAP/AFAP or 
sporadic adenomas with the same morphology (P=0.003 and P=0.03, respectively; 
Supplementary Figure 1). 
Figure 13. (A) Mutational status of adenomas in MAP, (B) FAP/AFAP. Columns represent the number 
of analysed adenomas (y axis) for each patient (x axis), whereas types of mutations and wild-type 
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Figure 15. (A) Pie chart shows the percentage of patients with single or multiple sporadic adenomas; (B) 
Mutational status of multiple sporadic adenomas. Columns represent the number of analysed adenomas (y 
axis) for each patient (x axis), whereas types of mutations and wild-type condition are reported in 
grayscale as per the legend below. WT, wild type. 
 
1.2 KRAS, NRAS, BRAF AND PI3KCA MUTATION ANALYSIS IN MATCHED 
ADENOMAS AND CRC OF THE SAME PATIENTS 
We investigated the occurrence of metachronous or synchronous CRCs in all 
patients included in the study: none among FAP/AFAP patients developed a CRC, 
whereas within the MAP subset, 50% of the patients (9/18 cases) exhibited at least one 
CRC (p=0.001) (Figure 16) (Supplementary table S1, S4). Interestingly, three MAP 
patients were diagnosed with CRC in the absence of adenomas and KRAS p.G12C 
mutation was observed in two out of these three CRCs. In the remaining six MAP 
patients we observed at least one CRC in presence of multiple adenomas and G>T 
transversion in codon 12 (p.G12C or p.G12V) of KRAS gene was the only substitution 
observed (Supplementary Figure 2).  
In the subset of sporadic patients, we could examine gene mutations in 15 
CRCs and matched adenomas of the same patients and we found that 67% of CRCs 
(10 of 15 tumors) showed KRAS mutations but also that 47% of these patients showed 
at least one KRAS mutated adenoma.  
As expected, the spectrum of KRAS mutations in the 10 mutated CRCs was extremely 
heterogeneous: 20% (2/10 cases) showed p.G12D mutation, 10% p.G13D (1/10 case), 
10% p.G12V (1/10 case) and 60% (6/10 cases) other mutations (Supplementary table 











None of the MAP CRC exhibited NRAS or BRAF mutations, while one NRAS mutation 
and one BRAF mutation were observed among the sporadic CRCs (Supplementary 
table S4-S5).  
Finally, we detected PIK3CA mutations exclusively in MAP CRCs (M1, M6, M17 and 



































2. L1 AND L1-MET HYPOMETHYLATION LEVELS IN 
COLORECTAL ADENOMAS AND CRCs 
EE 
As second approach to identify valuable risk biomarkers for colorectal carcinogenesis, 
we then evaluated hypomethylation levels of the L1 sequences in the three subsets of 
patients with adenomas previously analyzed. This analysis was performed in a total of 
168 adenomas using the two assays L1 and L1-MET and a linear correlation between 















Figure 17. Scatterplot shows a linear correlation between the values of L1 and L1-MET methylation of 
the all 168 adenomas analyzed. 
 
By using the lowest methylation value of normal mucosa (60%) as the methylation 
threshold, MAP and sporadic adenomas showed a similar hypomethylation profiles and 
exhibited a significantly higher frequency of hypomethylated samples compared to 
FAP/AFAP adenomas (p=0.034, p=0.005 and p<0.0001, p=0.0002 respectively) (Figure 
18).  Analyzing the levels of L1 and L1-MET methylation within the subsets of sporadic 
adenomas, we also observed than S-AdsC were more frequently hypomethylated 
(54,2% and 66,7% of cases with L1 and L1-MET analyses, respectively) than S-Ads 
(26,8% and 53,4% of cases with L1 and L1-MET analyses, respectively) with both 
assays.  





























Figure 18. (A) L1 and (B) L1-MET methylation percentages in normal colorectal mucosa, different 
adenoma groups (MAP, FAP/AFAP and sporadic); the methylation threshold was set at 60% as the 
lowest methylation value of normal mucosa for both L1 and L1-MET; black columns represent 
hypomethylated samples (<60%), while grey columns identify samples with a methylation level ≥60%. 
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To investigate the role of DNA hypomethylation during CRC cancerogenesis, we 
analyzed the levels of L1 and L1-MET methylation in 11 MAP and 15 sporadic CRCs 
included in this study. 
As expected, these two groups exhibited a significantly higher frequency of 
hypomethylated samples with respect to adenomas showing an increase of 
hypomethylation during tumor progression (63,6% and 73,3%, 90,9% and 78,6% of 


















Figure 19. (A) L1 and (B) L1-MET methylation percentages in MAP and sporadic cancers; the 
methylation threshold was set at 60% as the lowest methylation value of normal mucosa for both LINE-1 
and L1-MET; black columns represent hypomethylated samples (<60%), while grey columns identify 
samples with a methylation level >60%. 
 
Considering the distribution of L1 and L1-MET percentages in the multiple adenomas 
of each patient, methylation variability was higher in MAP and sporadic cases than 
FAP/AFAP patients. 
Notably, we found that at least one hypomethylated adenoma, evaluated with L1 assay, 
was detected in most of the MAP and sporadic patients (83%, 10/12 cases and 79%, 
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11/14 cases, respectively) respect to FAP/AFAP (43%, 3/7 cases) individuals           
(Figure 20).  
Similar results were also obtained with L1-MET assay and are reported in 
Supplementary Figure S3: in detail, MAP and sporadic patients showed at least one 
hypomethylated adenoma in 81% (9/11 cases) and 79% (11/14 cases), while FAP 







Figure 20. (A) Dot plots represent L1 methylation percentage in the multiple adenomas of MAP (A), 
FAP/AFAP (B) and sporadic (C) patients; black dots identify adenomas and red dots indicate 
KRAS/NRAS p.G12C mutated polyps; the green line symbolizes the methylation threshold (60%) for L1 
assay; bars show the mean values of L1 methylation percentage among adenomas of the same patients 
and light blu asterisks show the methyilation level of the corresponding carcinomas; symbols and colours 
are reported as per the legend below. WT, wild type 















































































3. EXPRESSION ANALYSIS AND CHARACTERIZATION  
OF L1-CHIMERIC TRANSCRIPTS  
 
3.1 RNA-SEQ ANALYSIS ON CRCs CHARACTERIZED FOR                                  
L1 HYPOMETHYLATION LEVELS       
We have investigated the causal link between local L1-hypomethylation and 
aberrant L1 chimeric transcripts (LCT) activation in genes harboring specific intronic 
L1 sequences. 
In silico analysis have revealed up to 911 new putative LCT across the genome, but 
only a few of these elements are implicated in cancer (81). 
In colorectal tumorigenesis, previous studies have demonstrated that the LCT 
expression may cause inadvertent activation of multiple proto-oncogenes including 
MET, RAB3IP, ACVR1C or blockade of onco-suppressor genes like TFPI-2 (84, 174). 
Therefore, in this work we focused on these four LCTs potentially involved in CRC 
development. 
RNA-Seq analyses of different transcript variants of these four genes were performed 
on 13 FFPE samples of histologically normal colonic mucosa and 32 FFPE CRCs, 
previously characterized in our lab for their clinico-pathological and molecular profiles 
(Sahnane 2015). This cohort of 32 CRCs were divided in four distinct groups based on 
L1 methylation levels: L1-group (L1>60.1%), L2-group (54.1%-60%), L3-group 
(45.8%-54%) and L4-group (<45.6%) and tumor RNA from cancers belonging to the 
same group were pooled. 
Using the UCSC Genome Browser Annotation and through specific bioinformatic tools, 
we found 4 transcript variants of ACVR1C, 8 for RAB3IP, 3 for TFPI-2 and 16 for MET. 
As the Heat Map shows (Figure 20), no significant difference of mRNA expression of 
ACVR1C, TFPI-2 and RAB3IP variants was observed when comparing L1/L2/L3/L4 
CRC groups. Only for the oncogene MET, expression levels of 3 transcript variants 
have surprisingly shown to be correlated significantly and in a linear fashion with L1 




































Normal MET variant  
L1-MET chimeric variant  
Figure 21. Heat Map of RNA-SEQ about ACVR1C, MET, 
RAB3IP and TFPI2 transcript variants in colorectal tissue 
samples (Normal), CRCs pool (Tumor), CRCs L1 (LINE_1), 









In detail, these 3 variants corresponded to: normal MET transcript and variant 2 of  
UCSC annotation with the same length respect to normal transcript; L1-MET fusion  
transcript, composed by L1 element within the intron 2 and the MET sequence from 



























3.2 IN SILICO CHARACTERIZATION OF THE L1-MET TRANSCRIPT 
 In-silico analyses confirmed the presence of the ORF0-containing L1 element, 
as reported (175-176), within the second intron of MET, between nucleotides g.51092C 
(c.1201-13172C) and g.57084C (c.1201-7191C) (GenBank Accession; #M80343.1) 
(GenBank Accession; #NG_008996.1) (Figure 23). The first methionine of ORF0 
mapped to nucleotide g.56654A (c.1201-7610A) of MET and its first nucleotide was 
taken as +1 of the L1- MET reference numbering. 
Figure 23. Graphical representation of the L1 element located within intron 2 of MET; L1 is inserted in 
the opposite orientation of MET with the sense promoter (SP) and the 5’-UTR encompassing the recently 
identified ORF0 sequence; ORF contains the antisense promoter (ASP) leading to the development of a 
chimeric L1-MET transcript (176). 
 
In order to evaluate the MET and L1-MET transcript expression, we designed a new 
assay to discriminate normal and chimeric variant. 
The forward PCR primer for L1-MET transcript was located inside the exon 1 of          
L1-MET that contains also the L1 promoter sequence, and the reverse primer was 
designed within the exon 2 of LI-MET (Figure 24). 
 
Figure 24.  Graphical representation of the L1-MET transcipt arising from the L1 element located within 













The assay’s specificity was tested by running the specific 81 bp amplicon on 3% 
agarose gel and by sequencing the specific band taking advantage of analysis of4 CRC 
samples already tested by RNA-Seq and resulted positive for L1-MET transcript  
(Figure 25). 


























3.3 HIGH LEVELS OF MET AND L1-MET TRANSCRIPTS IN 
HYPOMETHYLATED CRCs 
In order to validate RNA-Seq results, we performed qRT-PCR analysis to 
evaluate the expression levels of MET and L1-MET in cDNA samples from 9 L1 
(>60,1%) and 11 L4 (<45,6%) hypomethylated CRC and the results of these two tumor 
subsets with those obtained from 8 normal mucosa cDNA samples (Figure 26A).  
Interestingly, we observed a significant up-regulation of both transcripts (p<0.0001) in 
L4 vs L1 CRCs, confirming RNA-Seq data previously obtained (Figure 26B) 
(Supplemntary table S6).  
Figure 26. (A) Clustering analysis of L1 and L4 groups stratified for L1 methylation levels: L1 (9 CRCs, 
mean 63,1), L4 (11 CRCs, mean 40,2). (B) Boxplots show a significantly up-regulation of MET and            
L1-MET expression level in L4 group compared with those observed in L1 and NCMs (normal colon 







































































3.4 HIGH LEVELS OF MET AND L1-MET TRANSCRIPTS IN 
HYPOMETHYLATED COLORECTAL ADENOMAS 
In order to confirm the in silico results also in preneoplastic lesions, MET and 
L1-MET transcripts were evaluated in a cohort of 85 adenomas (13 MAP, 16 FAP and 
56 sporadic) and 8 normal colorectal mucosa samples that we used as calibrator to 
calculate the fold change expression.  
As box plot shows in Figure 27A, MET transcript was expressed at minimal basal level 
in all colorectal mucosa samples while an up-regulation was observed in 53% (45/85 
cases) of colorectal adenomas using as cut-off the 2X fold change            
(Supplementary table S6). 
Likewise, all colorectal mucosa samples exhibited levels of L1-MET transcript below 
the cut off whereas an up-regulation of the transcript was detected in 36% (31/85 cases) 
of colorectal adenomas (Figure 27B) (Supplementary table S7). 
Notably, a significant inverse correlation between L1-MET hypomethylation and     
MET/L1-MET transcript levels was observed in 75% and 51% of cases (p<0.0001) 
(Figure 28A and Figure 28B).   
Figure 27. (A) Level of MET and (B) L1-MET transcripts expression in 8 normal colon mucosa samples 




































































Figure 28. Columns represent the percentage of (A) MET and (B) L1-MET up-regulated and            
down-regulated samples with L1-MET methylation<60% and L1-MET ≥60%. FC, Fold Change. 
  
 
Moreover, 42% (23/55) of L1-MET hypomethylated adenomas showed up-regulation of 
both transcripts, while 42% (23/55) of these cases exhibited upregulation of either one 
or the other transcript. The remaining L1-MET hypomethylated adenomas (9/55; 16% 
of cases) exhibited down-regulation of both transcripts (Figure 29). 
Among samples with normal L1-MET methylation levels, we observed that 17% of  
cases showed up-regulation of either one or the other transcript (5/30) while only 1 case 
exhibited down-regulation of both transcripts; the remaining cases (24/30) showed 

























































Figure 29. (A) Top panels indicated samples with L1-hypomethylation (<60%; black) or without         
L1-hypomethylation (grey) ≥60% and samples with MET up-regulation (green), L1-MET up-regulation 
(blue), both transcritps up-regulation (red) and down-regulation (grey). (B) Colums represent the 
percentage of MET and/or L1-MET up-regulated samples with L1-MET methylation<60%                        
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4. CORRELATION BETWEEN CLINICO-
PATHOLOGICAL AND MOLECULAR ANALYSIS IN 
SPORADIC ADENOMAS 
 
Correlation analysis between molecular and clinico-pathological markers was possible 
for the subset of 80 sporadic adenomas. In detail, we correlated KRAS/NRAS mutational 
status, L1/L1-MET methylation levels and MET/L1-MET transcript expression with the 
5 clinico-pathological features currently used for classification of high risk adenomas. 
These characteristics include histology (TB/TBV/V), grade of dysplasia (Low/High), 
adenoma size (<10mm/≥10mm), adenoma site (right/left colon) and number of 
synchronous adenomas at diagnosis (<3/≥3). 
As reported in the Figure 29A, presence of KRAS/NRAS mutation was significantly 
correlated with TBV/V histology (p=0.0004), high grade of dysplasia (p=0.0001), 
adenoma size ≥10mm (p=0.002), L1-MET hypomethylation (p=0.04) and MET and/or 
L1-MET up-regulation (p=0.02) (Supplementary Table S3). 
The same correlation analysis was performed stratifying sporadic adenomas according 
to L1-MET methylation levels. Again we found that L1-MET hypomethylation was 
significantly correlated with TBV/V histology (p=0.02), adenoma size ≥10mm 
(p=0.03), presence of KRAS/NRAS mutations (p=0.04), L1 hypomethylation (p<0.0001) 
and MET or/and L1-MET up-regulation (p<0.0001) (Figure 29B and Supplementary 
Table S6). 
Finally, stratifying 56 sporadic adenomas according to MET and/or L1-MET transcripts 
expression levels, we observed that only L1-MET hypomethylation was significant 
correlated with MET and/or L1-MET up-regulation (p=0.001) (Supplementary Figure 















Figure 30. (A) Colums represent the percentage of cases with TBV/V histology, high grade of dysplasia, 
adenoma size ≥10 mm, L1-MET methylation <60% and up-regulation of MET or L1-MET stratifying 
sporadic adenomas according to mutational KRAS/NRAS status. (B) Colums represent the percentage of 
cases with TBV/V histology, high grade of dysplasia, adenoma size ≥10 mm, L1-MET methylation <60% 
and up-regulation of MET or L1-MET stratifying sporadic adenomas according to L1-MET methylation 
levels.     
Legend:TBV, tubulovillous adenoma, V villous adenoma; * 0.1<p ≤ 0.05; ** 0.001<p ≤ 0.01; 
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5. CORRELATION BETWEEN rs1800734 ALLELES AND 
MLH1 METHYLATION IN NORMAL COLORECTAL 
SAMPLES 
 
The single nucleotide polymorphism (SNP) rs1800734, that lies between the 
transcription start site and the ATG codon in the 5’ untranslated region of MLH1, has 
been assessed as a candidate for microsatellite unstable CRC susceptibility in a number 
of MSI CRC data sets while no evidences were found for unselected CRCs. Therefore, 
it was hypothesized that SNP rs1800734 may play a mechanistic role in the silencing of 
MLH1 during MSI cancer development (Allan et al., 2008; Campbell et al., 2009; 
Raptis et al., 2007; Whiffin et al., 2011). 
In order to detect potential differences of CpG island methylation patterns of MLH1 
gene and clarify the primary event leading to loss of MLH1 protein in MSI cancers, we 
devised a comprehensive analysis of the relationship between rs1800734 genotype and 
MLH1 methylation in normal colorectal samples.    
First of all, we analyzed by KASP assay the distribution of three genotypes AA/AG/GG 
of SNP rs1800734 in a cohort of 33 normal colorectal mucosa samples from patients 
undergoing colonoscopy without malignancies; in detail, the GG, AG and AA 











Figure 31. Pie chart shows the frequencies of the three SNP genotypes in our cohort of  normal colorectal 
mucosa samples. 
 













Subsequently, in the same normal samples we determined the methylation profiles 
across MLH1 CpG island and CpG shore by Miseq NGS analysis of bisulphite treated 
DNA amplicons.  
As expected, little or no methylation close to rs1800734 in Deng region C frequently 
involved in MLH1 silencing, was observed in any of the normal samples (Figure 32). 
There were increasing levels of methylation towards the upstream CpG island shore and 
interestingly these were higher in low-risk GG homozygotes than in the AG 
heterozygotes (p=0.011; insufficient AA samples were present for statistical analysis).  
 
 
Figure 32.  Scatter plot showing total methylation levels across all CpGs of MLH1 gene with 33 normal 








6. CORRELATION BETWEEN rs1800734 ALLELES, 
MLH1 METHYLATION AND MLH1 EXPRESSION IN MSI 
CRCs 
 
The MLH1 methylation analysis was also carried out in a cohort of 35 FFPE 
MSI CRCs in order to correlate the methylation status of promoter with the genotype of 
rs1800734. Due to fragmentation of DNA extracted from formaline-fixed tissues, this 
analysis was possible only in the CpG islands of the gene and was performed using MS-
MLPA ME-011 (Figure 10). 
In this cohort, the distribution of the three genotypes was the following: GG, AG and 

























MLH1 promoter methylation levels were variable but significantly higher in AA and 
AG patients than GG patients across the CpG island (P=0.0002) (Figure 35). 
Figure 36. Scatter plot showing methylation ratio of 5 probes used by MS-MLPA with 35 MSI tumours 
grouped by genotype.  
 
We interrogated these samples further to determine if these differences were specifically 
due to increase levels on the A allele in heterozygous patients. This analysis was 
performed by using bisulphite-treated DNA amplified by PCR, followed by long paired 
end reads and Miseq NGS to allow phasing of rs1800734 allele with methylation in 
region C. 
Despite variable levels of methylation between patients, we found in 15 patients that 
methylation on the A allele was significantly greater than the G allele (P=0.03)      




















Figure 36. Scatter plot showing allele specific methylation levels across CpGs close to rs1800734 with 
15 CRC samples grouped by genotype. 
 
Finally, in order to investigate the potential correlation between MLH1 methylation and 
expression, we analyzed MLH1 mRNA expression levels on the same 35 CRCs and we 
observed that results varied significantly with genotype (p=0.0001) (Figure 37).  
Notably, MLH1 mRNA expression were significantly correlated with methylation 








Figure 37. Boxplot showing total MLH1 mRNA levels in all 35 CRC samples grouped by genotype.       
























We carried out a similar analysis on colorectal cancer with matched normal data from 
The Cancer Genome Atlas (TCGA COADREAD, http://cancergenome.nih.gov/). We 
found that methylation in region C and at rs1800734 was significantly higher in 
tumours with AA and AG genotypes (Supplementary Figure 5A, n= 432, p=0.000133). 
When stratified by MSI status, the MSI tumours alone still showed a genotype-specific 
significant difference in methylation levels (Figure 38, n=157, p=0.00115), whilst MSS 
tumours showed no allele specific differences (Supplementary Figure 5B, n=275, 
p=0.627).  
 
Figure 38.  Scatter plot showing allele specific methylation levels across CpGs close to rs1800734  












Analysis of mRNA expression levels on the same data sets showed that these also 
varied significantly with genotype in all tumour samples (Supplementary Figure 5C, 
n=432, p=0.00153, ANOVA).  When stratified by MSI status the MSI tumour samples 
alone showed a highly significant difference between the genotypes (Figure 39, n=157, 
p=0.0006) whilst the MSS tumour samples showed no effect of genotype on expression 
(Supplementary Figure 5D, n=275, p=0.627).  
As in our MSI cancer data set, expression and methylation showed a highly significant 
correlation (p-value < 10-15, Pearsons). 
 
 














7. CORRELATION BETWEEN rs1800734 ALLELES, 
MLH1 METHYLATION AND MLH1 EXPRESSION IN 
VITRO  
 
 We wished to take a dynamic approach to determine if DNA methylation is the 
primary and causal event leading to MLH1 transcriptional silencing by analysing two 
MSI colorectal cancer cell lines, CO-115 and SW48, both with rs1800734 G/A 
genotype. Thus, we subjected the two cell lines to a treatment inducing global 
demethylation and measured allele-specific methylation and gene expression at baseline 
and specific time-points (4, 7 and 11 days after treatment). 
5-azacytidine and 5-aza-2'-deoxycytidine (AzaC) are chemical analogues of cytosine 
and inhibitors of DNA methylation and they cause a global loss of methylation when 
used to treat cell lines (177).  
At baseline, MSI CRC cell line CO-115 has very high levels of methylation at all CpGs 
analysed in the MLH1 promoter by MiSeq NGS (Mean=91%) and expression of MLH1 
is undetectable by qRT-PCR (Figure 40 and Figure 42).  
Figure 40. Line graphs showing methylation percentage levels at individual CpGs in the rs1800734 
region grouped by genotype. Each panel shows a control or time-point post AzaC treatment. The position 







Similar results were obtained by MS-MLPA analysis that confirmed biallelic 
methylation in untreated cells: for all the five probes (Figure 11) we observed MR 
(Methylation Ratio) ranging from 0.72 to 1.08 with a mean value of 0.96.   
After 4 days from the treatment, we observed a 50% reduction in DNA methylation      
(MR mean value=0.51) and progressive increase after 7 days (MR mean value=0.60) 
and 11 days (MR mean value=0.78) (Figure 41). 
Figure 41.  MS-MLPA analysis of the MLH1 gene in control cells and timepoints post AzaC treatment. 
A, B, C, D and E (intron) are the 5 probes used to analyze the MLH1 methylation. 
 
This loss of MLH1 methylation is accompanied by an equally dramatic re-expression of 
MLH1 mRNA peaking at 4 days post-AzaC treatment (P=0.007) and then starting to 
reduce by day 11 post-treatment (Figure 42). Again, there are allele specific differences 
at each stage with the risk (A) allele expressed at lower levels that the protective (G). 
Re-expression of MLH1 to similar levels was also seen in a second MSI CRC cell line, 
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Figure 42.  Bar graph shows total MLH1 mRNA expression and the allelic components of this 
expression in control cells and timepoints post AzaC treatment. Error bars show the standard 
error of the mean of replicates. Asteriks denote significant (1, p<0.05) or highly significant (2, 









































































CRC is a heterogeneous disease developing through different pathogenetic 
mechanisms. Although mortality has declined progressively in many Western countries 
mainly due to cancer screening programs and early detection of cancerous lesions, the 
discrimination of high risk adenomas is still challenging, both in hereditary syndromes 
and in sporadic cases. Actually, there is a strong need to establish clinically useful 
biomarkers for risk assessment and early detection of CRC. 
In the first part of this thesis, we focused on identification of new valuable 
molecular risk factors for the onset of CRC, studying both genetic and epigenetic 
characteristics, such as KRAS/NRAS/BRAF/PIK3CA mutations and DNA global 
hypomethylation in the early events of colorectal carcinogenesis. Our working 
hypothesis was that MAP, a rare hereditary colorectal polyposis associated to a rapid 
cancer progression due to inactive BER system and consequent accumulation of 
oxidative DNA damage (121), could be the appropriate model to validate new potential 
risk factors for colorectal cancerogenesis and also to study the interplay between genetic 
and epigenetic markers, when oxidative stress is the main etiological factor linked to 
cancer transformation. 
To verify this hypothesis, we initially selected 18 MAP patients carrying biallelic 
MUTYH germline mutations and a control set of 17 FAP/AFAP patients with 
pathogenic APC germline alterations. Interestingly, considering only the clinical data of 
these patients at the moment of FAP or MAP diagnosis, 50% of MAP patients showed 
at least one CRC with or without syncronous adenomas whereas no FAP patients 
exhibited a co-occurence of CRC during adenoma removal. This observation in our 
cohort is in line with previous data suggesting a more accelerated carcinogenesis in 
MAP than in FAP patients (125-126) and that a pathogenetic mechanism linked to 
oxidative DNA damage may be generally associated to a higher risk of CRC. 
As reported by two recent studies (178-179), we detected a two-fold higher level of 
somatic mutations in MAP adenomas respect to FAP/AFAP suggesting that a 
deficiency of MUTYH gene could lead to a mutator phenotype. As expected, in our 
cohort the KRAS p.G12C mutation was by far the most frequent alteration in MAP 
adenomas, and never detectable in comparable lesions from FAP/AFAP subset.      
KRAS p.G12C was frequently identified in both adenomas and carcinomas derived from 
the same MAP patients, confirming that the adenoma cell clones carrying this specific 







KRAS p.G12C may be used as the somatic hallmark of oxidative DNA damage in MAP 
disease (127, 180-181). 
Our findings reflect the well-known repair specificity of the MUTYH enzyme and the 
increased susceptibility to oxidative damage at the first base of the GGT sequence in 
KRAS codon 12. The peculiarity of the p.G12C mutation in this genomic region is 
further supported by the same transversion in the homologous BLAST-aligned 
nucleotide sequence of NRAS gene being detected in four of our MAP adenomas. So 
far, no other reports have documented the presence of NRAS mutations in MAP lesions. 
Although these alterations can be found in 10% of sporadic CRCs, they were shown to 
regulate homeostasis of colonic cells differently to KRAS alterations and were only 
occasionally detected in sporadic colorectal adenomas (182-183). 
In addition, we detected the co-occurrence of both KRAS p.G12C and PI3KCA 
mutations in 80% of the examined MAP carcinomas, suggesting that key mechanisms 
for cells to regulate cell survival, proliferation, and motility, such as Ras-ERK and 
PI3K-mTORC1 signaling, are often simultaneously inactivated in these type of CRCs. 
This result may have an important clinical impact since co-inhibition of both pathways 
has been successful in reducing tumor growth in xenograft cancer models and, 
importantly, also in genetically engineered mouse models (184-185). Moreover, the 
recent development of KRAS p.G12C specific inhibitors potentially opens new 
promising prospects for the treatment of patients affected by CRC with this somatic 
alteration (186-187). 
Regarding the histological phenotype, KRAS/NRAS mutations were more frequent in 
MAP adenomas with tubular architecture than FAP/AFAP lesions with the same 
morphology. Also this feature can be distinctive of MAP carcinogenesis since          
KRAS mutations were recently proposed as a risk factor for adenomas because they 
were mainly observed in tubulovillous and villous polyps rather than in tubular lesions           
(188-189). These data suggest that mutator phenotype in MAP could lead gene 
mutations also in preneoplastic lesions without aggressive morphological features. 
 In order to verify if somatic KRAS/NRAS/BRAF/PIK3CA mutations in polyps 
may generally represent a potential molecular marker for the risk of developing CRC 
(190-191), we chose to include in this study two groups of sporadic colorectal 
adenomas with different clinico-pathological aggressiveness, namely a first subset of  
56 sporadic adenomas (S-Ads) diagnosed in 45 patients who never developed a CRC 







(S-AdsC) from 17 individuals who developed a CRC at least one year after polyp 
removal.  
This analysis revealed that gene mutation frequencies were slightly higher in S-AdsC 
compared with S-Ads (46%, versus 38%, respectively) although this difference was not 
statistically significant. Globally, we found a higher frequency of KRAS/NRAS 
mutations in sporadic adenomas (40%) compared to previous works reporting a 
mutation frequency ranging from 10% to 20% (189,192). A possible explanation for 
this different result is that these studies analyzed consecutive series of unselected 
sporadic adenomas. By contrast, our series includes a large number of sporadic 
adenomas characterized by high-risk features, such as TBV/V hystotype, high grade of 
dysplasia, large size (≥10mm), multiple adenomas (ranging from three to six 
syncronous or metachronous adenomas), right colon site and development of a 
metachronous CRC (S-AdsC). In fact, KRAS/NRAS mutation frequency in our series is 
in line with previous works examining cohorts entirely composed of TBV/V adenomas 
or of in situ carcinomas (188). Moreover, not surprisingly, these frequencies were not 
very different from those generally reported in invasive CRC (193). 
An additional observation from our work was that 64% of patients showing multiple 
adenomas exhibited at least one mutated polyp, confirming that a condition of few 
synchronous/metachronous benign lesion may be per se relevant to detect high risk 
patients. Finally, contrary to MAP, the spectrum of KRAS/NRAS mutations in sporadic 
adenomas and carcinomas was extremely heterogeneous suggesting that different 
etiological factors may be involved in the acquisition of individual driver mutations 
(194). 
 The second aspect that we considered was the role of genome-wide                 
DNA hypomethylation as an early epigenetic alteration since it was observed both in 
hereditary and sporadic CRCs (169, 195-196). Likewise somatic gene mutations,           
L1 hypomethylation has been reported to occur early in colorectal carcinogenesis, 
including aberrant crypt foci and preneoplastic lesions as adenomas (72, 77, 197-199). 
However, although this marker has been recognized as a poor prognostic factor for 
increased cancer-related mortality and overall mortality in CRC patients (70-71), 
currently no studies have evaluated whether L1 hypomethylation in polyps may 







According to the working hypothesis presented above, we initially chose MAP 
adenomas as a model in which L1 hypomethylation rates were expected to be higher in 
comparison with FAP/AFAP lesions.  
Although no studies have so far evaluated this marker in MAP polyps, the rationale of 
this analysis came from several data published about the mechanisms of how oxidative 
stress decreases DNA methylation (89). Briefly, oxidized DNA lesions that are induced 
by ROS, such as 8-OHdG in CpG dinucleotides have been shown to strongly inhibit 
methylation of adjacent cytosine residues (91). Secondly, an unfixed 8-OHdG may 
introduce a G>T transversion resulting in the loss of CpG dinucleotides (95). Moreover, 
in an oxidative stress condition, with decreased availability of S-adenosylmethionine 
(SAM), depletion of the methyl pool in folate-deficient models has been shown to cause 
DNA hypomethylation (94). Recently, Kloypan et al. demonstrated that in bladder 
cancer and human kidney cell lines, L1 hypomethylation is associated with the 
oxidative stress-mediated activation of the ten-eleven translocation (TET) hydroxylase 
enzymes which cooperate with BER in controlling the formation and replacement of    
5-hydroxymethylcytosine (5hmC) (200). Finally, ROS are considered to be responsible 
for aberrant DNA methylation in different cancer models (200-204) and during chronic 
inflammation and inflammation-associated carcinogenesis, such as ulcerative colitis and 
Crohn’s disease (205-206). 
In agreement with our hypothesis, MAP adenomas were found to be more often 
hypomethylated than FAP/AFAP lesions, for both global genomic and intragenic 
sequences, as measured by L1 and L1-MET assays. Therefore, for the first time, we 
proposed a novel link between a BER defect and DNA hypomethylation in precursor 
lesions of CRC suggesting that unfixed 8-OHdG may strongly correlate not only with 
genetic lesions but also with aberrant DNA hypomethylation.   
In order to assess if L1 hypomethylation may generally represent a potential risk factor 
in adenomas, we used L1 and L1-MET assays to analyse this marker in the 80 sporadic 
adenomas both globally and stratyfing S-Ads and S-AdsC. This analysis revealed that 
about 50% of sporadic adenomas were L1-hypomethylated showing similar               
DNA hypomethylation frequencies of MAP adenomas. Considering the two subsets of 
sporadic adenomas, we observed that S-AdsC were more frequently hypomethylated 
than S-Ads, although this difference was not statistically significant. Moreover, in line 
with what observed for KRAS/NRAS mutations, the level of L1 and L1-MET 







matched adenomas of the same patients, suggesting that DNA demethylation is acquired 
early and retained in the adenoma-carcinoma transition. 
Finally, an interesting observation regards the different distributions of L1 and L1-MET 
methylation percentages in the multiple MAP or sporadic adenomas of the same patient 
compared with FAP/AFAP polyps. In this last group methylation levels were 
significantly less heterogeneous with respect to the first two subsets of patients. 
Globally, the stronger genetic and epigenetic heterogeneity among multiple MAP or 
sporadic adenomas suggests the presence of a field defect, the process of carcinogenesis 
initiating from multiple alterations in the colorectal mucosa which can lead to the clonal 
expansion of premalignant daughther cells in a particular field (207). In the colorectal 
mucosa, the identification of a field defect may indicate a higher risk of metachronous 
neoplastic lesions and coul help to identify which patients require a more radical 
surgery. Moreover, the most exciting use of field cancerisation theory is its potential 
application in chemoprevention (208). 
Taken together all these findings may suggest that DNA hypomethylation may play an 
early role in colorectal carcinogenesis characterizing a more aggressive clinical 
behavior of precursor lesions and cancers.  Further fuctional analysis in vitro could be 
useful to understand the molecular mechanism linking inactive BER and DNA 
hypomethylation and further research is needed to better define which specific etiologic 
factors may be involved in sporadic tumorigenic mechanisms associated with DNA 
hypomethylation. 
 Currently, few studies focused on the consequences of L1 hypomethylation in 
driving malignant progression (77, 82, 85, 174, 176, 209-211). L1 hypomethylation has 
been suggested to be a key event in cancer development because it results in 
retrotransposition throughout the genome leading to CIN (212-213). 
Moreover, in the context of CRC, Hur et al. in 2013 provided the first evidence for 
increased L1 hypomethylation in CRC metastasis, and systematically uncovered its 
relationship with locus-specific L1 hypomethylation within the proto-oncogene MET. 
More specifically, they demonstrated that global L1 hypomethylation correlates with 
hypomethylation of a specific L1 sequence which permit transcriptional activation of 
the aberrant chimeric transcript L1-MET with negative prognostic value and finally that 
higher expression of MET protein specifically correlates with higher levels of L1-MET 
transcription during development metastasis in CRC (84). Based on this study, we 







CRCs, may also be observed in preneoplastic lesions, characterizing the earlier phases 
of colorectal carcinogenesis. 
Before moving to adenomas, firstly we confirmed by RNA-Seq the strong association 
between L1 hypomethylation and MET/L1-MET expression in CRCs according to L1 
methylation levels. In line with Hur et al. (84), our data revealed that L1 methylation 
percentages of L1/L2/L3/L4 CRC groups were inversely correlated with MET/L1-MET 
transcript levels and that the more L1-MET sequence was hypomethylated, the more 
chimeric L1-MET/MET were overexpressed.  
Secondly, we designed a new assay to specifically distinguish L1-MET chimeric 
transcript from normal MET transcript and we validated RNA-seq results in L1 and L4 
CRC groups by using qRT-PCR analysis on the same tumor samples, applying this 
technique on small amounts of FFPE samples. For the first time, we demonstrated that 
the aberrant chimeric L1-MET transcript has already been expressed in a subset of 
colorectal adenomas through the same epigenetic mechanism demonstrated in CRC.  
Indeed our data confimed that more that 80% of L1-MET hypomethylated colorectal 
adenomas showed an abnormal upregulation of L1-MET and/or MET transcript 
suggesting that already in the early phases of colorectal carcinogenesis the molecular 
mechanism regulating MET expression may be altered through L1-hypomethyaltion. 
In conclusion, our data indicate that, in addition to well-assessed specific 
mutations, the early steps of oxidative DNA damage-induced colorectal carcinogenesis 
are characterised by decreased DNA global methylation and specific L1-MET 
hypomethylation. Moreover, our results emphasise the idea that genetic and epigenetic 
mechanisms strengthen each other in driving colorectal tumourigenesis. Because of the 
clinical recommendations for recently established aspirin-based chemoprevention 
strategies (214), these results appear to be interesting in improving the identification of 
individuals who are most likely to benefit from a prophylactic aspirin regimen. 
 Finally, we conclude that both genetic and epigenetic markers such as 
KRAS/NRAS mutations, L1-hypomethylation and transcriptional activation of aberrant 
chimeric transcripts such L1-MET deserve to be evaluated in a future diagnostic 
algorithm in which both clinico-pathological and molecular factors may be integrated 
for a classification of patients with colorectal adenomas into different categories of risk.  
A preliminary correlation analysis between these three molecular markers and the main 
clinico-pathological factors currently used for high risk colorectal adenomas (10) 







associated to clinical and morphological features suggestive of aggressive behavior in 
precursor lesions of CRC.  
Future perspectives of this study will include the validation of these results in an 
independent and larger series of sporadic adenomas in order to assess a robust 
multivariable analysis that may evaluate the independent contribution of each factor. 
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 In the second part of this thesis, we focused on the correlation between         
MLH1 SNP rs1800734 and MLH1 mehylation-driven silencing in MSI CRCs.gene.ksp 
The accumulation of a number of low-risk and low-penetrance variants contributes to 
significant cancer risk. However, despite the fact that the majority of SNPs are located 
in non-coding regions of the genome, their diverse role in disease pathogenesis, 
including CRC, are steadely becoming established through both experimental and 
computational methods (149, 150, 215). 
Of particular interest to my research project was the MLH1 promoter SNP rs1800734   
(-93G>A), located in the CpG island of MLH1 promoter. The variant A allele of this 
SNP shows a strong association with MLH1 CpG island hypermethylation, loss of 
MLH1 expression, MMR deficiency, and MSI sporadic CRC (157-161). Further, the 
allelic variant of rs1800734 has a functional consequence in that it decreases the 
transcriptional activity of MLH1 in CRC cell lines (163). This SNP has also 
demonstrated to be associated with increased risk of glioblastoma, gastric cancer, lung 
cancer, and ovarian cancer (216-219). 
These epidemiological data collected in the last years about SNP rs1800734 suggested 
us to investigate the mechanistic basis of promoter hypermethylation and transcriptional 
silencing of MLH1. To date, the relationship between the initiating genetic events 
responsible for tumorigenesis (e.g.,acquisition of activating mutations in oncogenes or 
presence of specific SNP) and the subsequent promoter hypermethylation and 
transcriptional silencing remain to be determined. To this aim, we decided to examine 
in-depth the mechanism of MLH1 silencing in order to hypothesize a general 
mechanism of gene inactivation due to epigenetic alterations.  
We have confirmed that the SNP rs1800734 in the promoter of MLH1 is associated with 
the risk of sporadic MSI CRC. This strong influence on the mismatch repair pathway 







expression of the mismatch repair pathway protein, MLH1. ffffffffffffffffffffffffffffffffff                                            
Our results demonstrate that a significant allele specific effects are seen on both 
methylation and mRNA expression in MSI cancers in our own and publically available 
data sets. As expected the risk (A) allele leads to significantly higher methylation levels 
and this strongly correlates with lower mRNA expression.  
Conversely, the risk (A) rs1800734 allele has no measurable repressive effect on MLH1 
in normal colon tissues, even using highly sensitive techniques, and in fact associates 
with reduced DNA methylation at the upstream CpG island shore, in line with previous 
observations (165).  
We have also clearly demonstrated that DNA methylation is necessary for                
MLH1 transcriptional silencing by treating with AzaC, removing methylation and 
demonstrating re-expression of MLH1 in MSI cells. This result implies that methylation 
is indeed the primary cause of MLH1 silencing in sporadic MSI cancers. Interestingly, 
even in this engineered situation the risk (A) allele is more prone to acquire methylation 
and its mRNA is re-expressed at lower levels. The reason could be that the A allele is 
more readily methylated could be due to the lack of binding of the TFAP4 transcription 
factor as shown by Lui et al. (164).  
 Premilary data not shown confirmed that there is indeed a strong bias in TFAP4 
binding in unmethylated CRC cells and that this binding is inversely correlated with 
DNA methylation post AzaC treatment in MSI cells.  
However, it is unlikely that TFAP4 may be the only transcription factor binding across 
rs1800734 and publically available genome wide ChIP-seq experiments show multiple 
proteins binding in the region (ENCODE, UCSC).  
Indeed, TFAP4 has been shown to belong to a class of enhancer binding factors that are 
important for co-factor recruitment and activation (220). This suggests that it could be a 
major factor in determining protein binding and potentially chromatin landscape across 
the region. The fact that TFAP4 also binds allele specifically to another disease 
associated SNP (rs12722522, Type 1 diabetes (221) suggests it might play a more 
generalised role in a subset of SNP trait associations, acting to recruit activating factors 
in an allele specific manner. 
Liu et al. suggest that allele specific TFAP4 binding at rs1800734 may exert an effect 
on the cancer pathway via long range interactions with the promoter of the DCLK3 
gene, causing enhanced expression of genes related to epithelial-to-mesenchymal 







We failed to detect significant DCLK3 expression in either our MSS or MSI cell lines 
using sensitive Q-PCR based techniques.xkxkxkxkxkxkkxkxkxkxkxkkjdjdjdjdjdjdjdjjdj                                                                    
We have clearly demonstrated that rs1800734 is only associated with an increased risk 
of MSI cancers and only modifies methylation in these cancers. Thus, it seems unlikely 
that a gene with no known role in MMR plays the primary or causative role in 
rs1800734 associated cancer risk.  
 Our data, taken together with other studies described above, support the 
prevailing hypothesis that MLH1 repression is the main mechanism by which 
rs1800734 confers cancer risk. Since the majority of our MSI cancers (23/35) carry a 
BRAF V600E mutation we suggest it is likely that rs1800734 influences the acquisition 
of methylation via the BRAF/MAFG pathway described by Fang et al. (103).  
Figure 43 represents our proposed model in which TFAP4, with co-factors binds within 
the promoter region on the G protective allele. This restricts the access of the BRAF 
activated MAFG complex and consequently reduces the spread of DNA methylation 
spreading from the CpG island shore.  On the A allele TFAP4 binding occurs less 
frequently or with lower affinity allowing MAFG access and methylation spreading.  
While the functional role of rs1800734 in the pathways of CRC development is 
becoming clearer, it is also interesting to note how readily the accumulation of MLH1 
promoter methylation could be reversed resulting in re-expression of MLH1. The 
importance of MLH1 promoter methylation in other cancer types is less well understood 
however it is frequently found in endometrial, gastric cancers as well as lung, bladder, 
and some haematological malignancies (222-226). Drugs such as Azacitidine that 
inhibit DNA methylation are already approved for the treatment of some cancers. 
However with the advent of CRISPR technology, more precise demethylation is now 
possible (227) and could be harnessed in the design of future therapies. 
 










Fig 43. (Upper Panel) The protective allele (G, green triangle, upper panel) binds TFAP4 (yellow) which 
protects the promoter (black arrow) from BRAF and MAFG (blue) directed methylation and/or 
methylation spreading from the CpG island shore. The grey shaded area represents methylation levels 
across the region. (Lower Panel). The risk allele (A, red inverted triangle) does not bind TFAP4 allowing 
MAFG and cofactors to mediate DNMT3B methylation in the promoter region causing transcriptional 



























 The early steps of oxidative DNA damage in MAP carcinogenesis are 
characterized by a specific pattern of somatic mutations;                                                     
kkkk 
 MAP adenomas and carcinomas show a decreased DNA global methylation 
and specific L1-MET hypomethylation; 
 
  DNA hypomethylation and expression of L1-MET chimeric transcript may 
play an early role in colorectal carcinogenesis characterizing a subset of 
more aggressive precursor lesions and cancers; 
 
 Both genetic and epigenetic markers such as KRAS/NRAS mutations,                      
L1-hypomethylation and transcriptional activation of L1-MET deserve to be 
evaluated in a future diagnostic algorithm in which both                         
clinico-pathological and molecular factors may be integrated for a 
classification of patients with colorectal adenomas into different categories 
of risk. 
 
- - - - - - - - - - - - - -   
 
 In normal colon tissue, allele-specific differences about rs1800734 exist in 
methylation of MLH1 CpG shore; 
 
 Allele-specific differences in both MLH1 promoter methylation and 
expression are present in MSI cancers; 
 
 The MLH1 transcriptional repression is dependent on DNA methylation and 
can be reversed by a methylation inhibitor; 
 
 We proposed a new model to explain how the rs1800734 may regulate the 



































Supplemtary Table S1. Histopathological and molecular features of 52 colorectal adenomas from 15 MAP patients.  
MAP 
patients 
MUTYH germline mutations 
 





Site Dysplasia % Methylation Mutation 





51 A1 TB Cecum low 61.43 56.23 WT WT 
 A2 TB NA NA 63.20 62.50 WT WT 
 A3 TB NA NA 54.08 58.97 WT WT 
 A4 TBV Right colon low 56.25 N.A. p.G12C WT 




48 A1 TB Sigma low 75.33 67.33 WT p.G12S 
 A2 TBV Sigma low 66.60 69.57 WT WT 






79 A1 TB Cecum low 68.05 67.07 p.G12C WT 
 A2 TBV Rectum low 45.45 64.3 WT p.G12C 





47 A1 TB Colon NOS low 59.00 62.53 p.G12C WT 
 A2 TB Colon NOS  low 61.05 59.80 p.G12C WT 
 A3 TBV Colon NOS low 61.45 60.87 p.G12C WT 
 A4 TB Colon NOS low 62.73 59.37 WT p.G12V 




44 A1 TBV  Sigma high 46.93 54.37 WT WT 
 A2 TB Right colon low 56.85 63.13 WT WT 
 A3 TBV Right colon high 55.98 57.2 WT WT 
 A4 TB Right colon low 62.15 53.4 WT p.G12C 
 A5 TB Right colon high 61.58 63.9 WT WT 
 A6 TB Right colon low 64.78 58.36 WT WT 



























40 A1 TBV Rectum low 53 59.9 p.G12C WT 
 
 A2 TB Rectum low 62.43 64.8 WT WT 
 A3 TBV Rectum low 69.28 64 WT WT 
 A4 TBV Rectum low 54.6 55.73 p.G12C WT 
 A5 TBV Rectum low 56.4 55.88 p.G12C WT 
 A6 TBV Rectum low 61.95 62.53 p.G12C WT 
 A7 TB Rectum low 61.2 62.63 p.G12C WT 




           p.Glu466del. 
43 A1 TB Right colon low 62.28 62 WT WT 
 A2 TB Left colon low 68.85 62.1 WT WT 
 A3 TB Right colon  low 59.55 61.5 p.G12C WT 
 A4 TB Right colon low 73.2 68.36 WT WT 
 A5 TB Rectum low 64.95 65.73 WT WT 
 A6 TBV Right colon low 65.15 61.63 p.G12A WT 




50 A1 TB Right colon  low 71.2 63.96 p.G12C WT 
 A2 TBV Rectum low 70.61 63.4 p.K117N WT 





65 A1 TB Colon NOS low 52.05 52.93 WT WT 







39 A1 TBV NA low 60.98 N.A. WT WT 
 A2 TB NA low 51.5 54.2 WT WT 
M16 c.536A>G/ 
c.933 +3A>C  
p.Y179C/ 
p.Gly264TrpfsX7 
54 A1 TB Hepatic 
flexure 
low 60.23 56.9 WT WT 
 A2 TBV Cecum low 55.78 54.1 WT WT 
 A3 TB Colon NOS low 64.06 56.6 WT WT 
 A4 TB Cecum low 60.9 59 p.G12C WT 
 A5 TB Colon NOS low 58.55 57.7 WT WT 
 A6 TBV Colon NOS low 53.4 55.6 WT WT 
M18 c.1012C>T/ 
1187G>A 
p.Gln338*/G396D 50 A1 TBV Right colon high 58.88 59.7 WT WT 
    A2 TB Right colon low 65.1 60.33 WT WT 







Supplemtary Table S2. Histopathological and molecular features of 36 adenomas from 17 FAP/AFAP patients. 
 
FAP/AFAP   
patients 
APC germline mutations 
 





Site Dysplasia % Methylation Mutation          
 L1 L1-MET KRAS NRAS 
F1 c.3577_3578 delCA 
 





31 A1 TB Sigma low 54.10 58.80 WT     WT 
 A2 TB Rectum-
Sigma 
low 66.75 64.47 WT WT 
 A3 TB Colon 
NOS 





38 A1 TB Right 
colon 
low 60.33 61.53 WT WT 
F4 c.2524_2525 insA p.Asp842 GlufsX74 37 A1 TB Sigma low 67.53 64.83 p.G12V WT 
 A2 TB  Right 
colon 
low 63.43 NA WT WT 
F5  c.4147_4148 delAT 
 
p.Met1383ValfsX2 30 A1 TB     Left 
colon 
NA 68.78 60.43 WT WT 
 A2 TBV     Left 
colon 
low 60.40 53.83 p.G12S WT 
 A3 TBV Sigma low 64.03 61.60 p.G12V WT 
F6  Whole gene del.  48 A1 TBV NA low 67.33 61.47 p.G12D WT 
F7 c.2734delT p.Leu912  TyrfsX3 21 A1 TB Colon 
NOS 
low 71.95 60.63 WT WT 
F8 c.2734delT p.Leu912 TyrfsX3 23 A1 TB Sigma low 64.58 69.00 WT WT 
F9  c.677_684  
delAGGACATAinsTTTC 




 A2 TBV NA low 59.8 NA p.G12V WT 
F10 c.3495-3496insA p.Tyr1166 IlefsX1 19 A1 TB Sigma low 64.38 61.30 WT WT 
F11  c.745A>T p.Lys249X 37 A1 TB Rectum low 66.50 62.77 WT WT 
F12 c.2626C>T p.R876X 37 A1 TBV Rectum-
Sigma 
















F13  c.3926del5 p.Glu1309AspfsX3 42 A1 TB Left colon low 60.73 61.2 WT WT 
 A2 TB Left colon low 61.88 63.07 p.G13C WT 
 A3 TB Colon 
NOS 
low 60.3 59.63 WT WT 
 A4 TBV Colon 
NOS 
low 57.83 58 WT WT 
 A5 TB Colon 
NOS 
low 60.13 58.93 WT WT 
 A6 TBV Ampulla 
of Vater 
low 65.5 61.53 WT WT 
 A7 TBV Colon 
NOS 
high 61.1 62.73 WT WT 
 A8 TB Left colon  low 59.43 60.33 WT WT 
 A9 TB Right 
colon 
low 62.1 57.83 WT WT 
     
    F14 
c.4549_455 delCAGA p.Gln1517LysfsX5 57 A1 TB Duodenum 
 
low 63.1 63.6 WT WT 
 A2 TB Ampulla 
of Vater 
low 65.38 63.03 WT WT 
 A3 TB Ampulla 
of Vater 
low 65.1 61.13 WT WT 
F15 t(5;7) (q22;p15)  33 A1 TB Rectum low 62.63 62.56 WT WT 
F16 c.637C>T p.R213X 22 A1 TB Rectum low 70.18 67.3 NA NA 
 A2 TB Right 
colon  
low 72.98 68.13 WT WT 
 A3 TB Left colon  low 70.25 64.8 WT WT 
 A4 TB Rectum low 
 
61.1 68.06 WT WT 




















% Methylation Mutation 
    L1 L1-MET KRAS NRAS 
S-Ads            




66.53 65.13 p.G12D WT 
S2 66 A1 TB Rectum low  6 3 61.38 65.60 WT WT 
S3 66 A1 TBV Sigma low  18 1 59.48 62.37 WT WT 
S4 77 A1 TBV Sigma NA 18 1 60.88 63.03 WT WT 
S5 54 A1 TBV Sigma high 7 2 63.03 66.40 WT WT 
S6 82 A1 TBV Sigma low  18 1 62.03 65.67 WT WT 
S7 75 A1 TBV Sigma low  5 1 62.03 66.03 WT WT 
S8 72 A1 TBV Sigma low  10 3 59.05 66.37 p.G12V WT 




60.25 62.17 p.G12V WT 
S10 71 A1 TBV Sigma high 6 2 62.83 63.40 p.G12D WT 
S11 50 A1 TBV Colon NOS low  2 2 60.55 63.43 p.G12D WT 
S12 67 A1 TB Colon NOS low  1 2 62.4 61.2 WT WT 




60.05 59 WT WT 




63.13 62.9 WT WT 




63 62.1 WT WT 
S16 59 A1 TB Colon NOS low 2 3 60.38 62.23 WT WT 
  A2 TB Colon NOS low 2  60.73 62.56 WT WT 
  A3 TB Colon NOS low NA  61.06 62.06 WT WT 
S17 57 A1 TB Sigma low 2 4 62.75 60.06 WT WT 
  A2 TB Left  colon  low 2  60.07 60.36 WT WT 
S18 61 A1 TB Colon NOS low  4 2 67.3 68.6 WT WT 







S19 61 A1 TB Ascending 
colon 
low  3 6 62.9 67 p.G12A WT 
S20 73 A1 TB Colon NOS low  4 2 70 65.03 WT WT 




69.23 65.07 WT WT 
S22 68 A1 TBV Left colon low 9 1 60.88 58.40 p.G12E WT 
S23 64 A2 TBV Left colon low 12 1 59.43 56.93 WT WT 
S24 57 A1 TBV Left colon  low 5 1 65.43 60.47 WT WT 
S25 52 A1 TBV Left colon low 12 1 58.10 57.57 WT WT 
S26 64 A1 TBV Right colon low 6 1 59.60 58.87 WT WT 
S27 73 A1 TBV Left colon low 10 2 59.13 61.97 WT  WT 
  A2 TBV Left colon low 15  62.45 60.37 WT  WT 
S28 61 A1 TBV Left colon low 10 1 62.08 58.57 p.G12S WT 
S29 38 A1 TBV Right colon high 10 2 56.60 56.27 p.G13D WT 
 44 A2 TB Right colon high 16  53.80 55.77 p.G13D WT 
S30 50 A1 TBV Right colon  low 6 1 60.33 57.47 WT  WT 
S31 69 A1 TBV Left colon low >20 1 58.33 57.40 WT WT 
S32 64 A1 TBV Right colon low 22 2 57.25 54.5 p.G12D WT 
  A2 TBV Right colon low 22  58.2 55.9 p.G12D WT 
S33 49 A1 TBV Left colon low 3 1 60.4 58.3 WT WT 
S34 63 A1 TBV Right colon low 5 1 59.3 58.0 WT WT 
S35 75 A1 TBV Left colon low 20 2 60.1 56.5 p.G13D WT 
  A2 TBV Left colon low 20  58.63 55.9 p.G13D WT 
S36 59 A1 TB Left colon low 5 1 61.75 57.4 WT WT 
S37 74 A1 TBV Right colon low 5 2 53.38 50.1 WT p.G12D 
  A2 TB Right colon low 3  67.6 53.4 WT WT 
S38 66 A1 TB Left colon low 5 2 58.1 58.3 WT WT 
S39 76 A1 TBV Left colon high 30 4 56.7 51.2 p.G12D WT 



















  A4 TBV Left colon high 30  53.7 49.2 p.G12S WT 
S40 70 A1 TB Right colon low 10 1 59.1 57.1 WT WT 
S41 55 A1 TBV Left colon high 15 2 57.9 57.5  WT WT 
S42 63 A1 TBV Left colon low 8 1 57.6 57.7 WT WT 










S45 62 A1 TBV Left colon high 15 1 77.0 59.7 p.G12V WT 
S-AdsC            
S46 65 A1 V Left colon low 15 1 58.20 57.93 WT  WT 
S47 60 A1 V Left colon high 30 3 55.18 54.23 p.G13D WT 
S48 72 A1 TBV Right colon high 30 3 62.70 60.87 p.Q61L WT 
  A2 TBV Right colon high 18  61.28 59.83 p.G12A WT 
S49 58 A1 TBV Right colon high 13 1 59.23 60.83 WT  WT 
S50 76 A1 TBV Left colon low 13 3 67.90 58.87 WT  WT 








  A2 TB Right colon low 20  57.10 61.93 p.G12D WT 
















S56 82 A1 TB Right colon low >20 3 55.55 59.03 WT WT 
  A2 TB Right colon low > 20  58.15 60.73 WT WT 
S57 66 A1 TB Right colon low <20 2 48.48 51.40 WT WT 
 69 A2 TB Right colon low >20 4 61.23 59.23 p.G12A WT 
S58 74 A1 TB Left colon low 6 1 55.95 58.47 WT WT 








Legend: S-Ads, patients who have never developed a CRC during a follow-up of ten years; S-AdsC, patients who developed a CRC at least one year after polyp 














































































  A2 V Left colon high 55  63.50 57.67 p.G12V WT 
  A3 V Left colon high 15  52.63 58.07 p.G12V WT 










Supplemtary Table S4. Molecular features of the 11 MAP adenocarcinomas. 
  
 







                MUTYH germline mutations Age at  
diagnosis 
Adenocarcinoma  Site % Methylation Mutation 
           DNA change              Protein        L1 L1-MET KRAS NRAS BRAF PI3KCA 





51 CRC NA 58.70 57.73 p.G12C WT WT p.Q546K 




47 CRC Ascending colon 63.00 59.97 p.G12C WT WT WT 
    CRC Ascending colon 59.55 59.54 p.G12C WT WT WT 
M6  c.536A>G/ 
c.1105G>T   
p.Y179C/ 
p.E369X 
42 CRC Colon NOS 52.10 51.90 p.G12C WT WT p.Q546K 





40 CRC Rectum 62.52 58.90 p.G12C WT WT WT 
    CRC Right colon 65.23 61.47 p.G12V WT WT WT 




47 CRC Rectum 56. 
33 
57.13 p.G12C WT WT WT 




57 CRC Right colon 53.03 51.46 WT WT WT WT 





54 CRC Rectum 64.45 59.63 p.G12C WT WT WT 





































Age at  
diagnosis 
Adenocarcinoma  Site % Methylation Mutation 
  L1 L1-MET KRAS NRAS BRAF PI3KCA 
S48  72 CRC Right colon 55.6 56.4 p.G12V WT WT WT 
S49  58 CRC Right colon 49.0 49.7 p.G12A WT WT WT 
S50 76 CRC Right colon 62.4 62.5 p.G12A WT WT WT 
S51 78 CRC Right Colon 57.0 54.9 WT WT WT WT 
S52 67 CRC Left Colon 61.3 55.4 p.G12D WT WT WT 
S53 82 CRC Left Colon 59.6 60.2 p.G12D WT WT WT 
S54 69 CRC Left Colon 58.3 53.5 p.G12S WT WT WT 
S55 68 CRC         Right Colon 55,1 56.4 p.G13D WT WT WT 
S56 82 CRC        Right Colon 56.5 57.9 WT WT WT WT 
S57 72 CRC        Right Colon 61.1 60.2 p.G12A WT WT WT 
S58 74 CRC      Left Colon 62.9 58.2 WY WT p.V600E WT 
S59 61 CRC       Left Colon 49.5 50.7 WT WT WT WT 
S60 63 CRC       Left Colon 54.8 55.1 WT WT WT WT 
S61 72 CRC        Left Colon 54.6 NA p.G12S WT WT WT 































Legend: CRC, colorectal cancer; L1 group CRCs; L4 group CRCs; FC, Fold Change. 
 
 
Patient Adenocarcinoma % Methylation Expression levels (FC) 
 L1-MET  MET L1-MET 
L1-1 CRC 61.4  1.02 1.87 
L1-2 CRC 60.9  084 1.9 
L1-3 CRC 63.97  0.67 1.79 
L1-4 CRC 60.47  1.61 2.32 
L1-5 CRC 61.73  2.26 1.98 
L1-6 CRC 64.4  3.68 1.68 
L1-7 CRC 63.4  1.85 1.2 
L1-8 CRC 55.7  2.44 3.17 
L1-9 CRC 55.9  1.45 2.4 
L4-1 CRC 54  6.86 7.26 
L4-2 CRC 57.43  6.23 8.93 
L4-3 CRC 52.8  4.43 6.23 
L4-4 CRC 56.4  6.19 4.56 
L4-5 CRC 50.26  4.75 7.26 
L4-6 CRC 56.3  4.59 6.1 
L4-7 CRC 53.55  6.23 9.38 
L4-8 CRC 40.8  5.48 8.03 
L4-9 CRC 53.1  3.86 3.87 
L4-10 CRC 48.5  2.05 3.39 







Supplemtary Table S7. MET/L1-MET expression levels of 13 MAP, 16 FAP and 56 sporadic adenomas analyzed. 
 
Patient Adenoma % Methylation Expression levels (FC) 
 L1-MET  MET L1-MET 
M2 A2 69.57  0.38 0.00 
M4 A1 62.53  0.76 2.23 
M4 A2 59.8  2.04 6.19 
 A3 60.87  0.42 2.68 
 A4 59.37  1.72 6.45 
M9 A1 59.9  5.17 8.63 
 A2 64.8  1.29 0 
 A4 55.73  3.51 5.24 
 A5 55.88  2.60 6.15 
 A6 62.53  0.65 0 
 A7 62.63  1.16 0 
M18 A1 59.7  2.69 6.68 
 A2 60.33  2.38 3.05 
F13 A1 61.2  0.93 0 
 A2 63.07  0.50 0 
 A3 59.63  1.85 5.31 
 A4 58  2.66 5.74 
 A5 58.93  1.66 5.06 
 A6 61.53  0.45 0 
 A7 62.73  0.93 0 
 A8 60.33  0.99 0 
 A9 57.83  3.34 4.86 
F14 A1 63.6  0.63 0 
 A2 63.03  0.52 0 







F15 A1 62.56  0.63 0 
F16 A2 68.13  0.51 0 
 A3 64.8  0.44 0 
 A4 68.06  0.52 0 
S22 A1 58.40  0 0 
S23 A2 56.93  13.98 0 
S24 A1 60.47  0 0 
S25 A1 57.57  0 0 
S26 A1 58.87  15 0 
S27 A1 61.97  0 0 
 A2 60.37  0 0 
S28 A1 58.57  12.55 0 
S29 A1 56.27  1.23 0 
 A2 55.77  5.80 17.15 
S30 A1 57.47  0 0 
S31 A1 57.40  1.12 0 
S32 A1 54.5  1.8 0.44 
 A2 55.9  2.2 2.31 
S33 A1 58.3  3.01 0 
S34 A1 58.0  2.81 2.46 
S35 A1 56.5  2.84 1.53 
 A2 55.9  2.79 0.67 
S36 A1 57.4  2.65 0.81 
S37 A1 50.1  3.48 0 
 A2 53.4  3.03 0 
S38 A1 58.3  4.31 2.36 
S39 A1 51.2  2.56 3.89 
 A2 48.8  3.22 3.20 







 A4 49.2  2.07 3.01 
S40 A1 57.1  3.81 0.43 
S41 A1 57.5  3.18 4.75 
S42 A1 57.7  3.45 6.63 
S43 A1 59.1  4.72 4.69 
S44 A1 56.1  3.58 2.02 
S45 A1 59.7  3.65 3.91 
S46 A1 57.93  6.75 0 
S47 A1 54.23  21.26 0 
S48 A1 60.87  2.17 0 
 A2 59.83  2.78 1.10 
S49 A1 60.83  0.60 0 
S50 A1 58.87  2.15 0 
 A2 59.43  1,05 0 
S51 A1 59.27  1.48 0 
 A2 61.93  0.97 0 
S52 A1 59.47  7.01 6.87 
S53 A1 62.97  3.08 0 
S54 A1 60.30  0.71 0.66 
S55 A1 52.43  3.16 0 
S56 A1 59.03  5.17 0 
 A2 60.73  0.45 0 
S57 A1 51.40  3.59 0 
 A2 59.23  2.35 0 
S58 A1 58.47  1.78 0 
S59 A1 57.23  1.64 6.08 
S60 A1 60.03  1.23 0 
S61 A1 62.23  2.57 0 















 A3 58.07  0.42 8.08 







Supplemtary Figure S1. Correlation between mutational status and tubular architecture of MAP 
adenomas compare to that FAP/AFAP and sporadic (B). Columns represent the number of analysed 





























































Supplemtary Figure S2. KRAS/NRAS mutations in the MAP and sporadic CRC cohort. (A) Percentage of mutations in MAP and sporadic CRCs; columns represent 
the mutation frequencies and KRAS/NRAS mutations or wild-type (WT) status are indicated in gray scale as reported as per the legend below. 
(B) Spectrum of KRAS/NRAS mutations in two groups of CRC (MAP and sporadic) are reported in pie charts and colours show the different types of KRAS/NRAS 


















Supplemtary Figure S3. (A) Dot plots represent L1-MET methylation percentage in the multiple 
adenomas of MAP (A), FAP/AFAP (B) and sporadic (C) patients; black dots identify adenomas and red 
dots indicate KRAS/NRAS p.G12C mutated polyps; the green line symbolizes the methylation threshold 
(60%) for L1 assay; bars show the mean values of L1 methylation percentage among adenomas of the 
same patients and light blu asterisks show the methyilation level of the corresponding carcinomas. 
symbols and colours are reported as per the legend below. WT, wild type. 
 





























































































Supplemtary Figure S4. (A) Colums represent the number of cases with L1-MET methylation <60% and 






































MET and/or L1-MET 
up-regulation
MET and/or L1-MET 
down-regulation


























Supplemtary Figure S6.  Increase in MLH1 expression levels in SW48 (MSI) cells after treatment with 
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